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Resumen 
Las infecciones del trato urinario (ITUs) constituyen una de las infecciones 
bacterianas más frecuentes tanto a nivel comunitario como hospitalario. Durante los últimos 
años se ha descrito un aumento en las tasas de resistencia a los antibióticos así como de las 
tasas de recurrencias en pacientes con ITU, teniendo un alto impacto tanto en la morbilidad 
como en la mortalidad en todo el mundo. Para poder hace frente a este problema debemos 
entender los procesos evolutivos que dan lugar al desarrollo de resistencias durante el 
tratamiento de las ITUs. Por ello, el objetivo de esta tesis ha sido evaluar el impacto de las 
condiciones fisiológicas del tracto urinario sobre la actividad de ciprofloxacino y 
fosfomicina frente a Escherichia coli.  
En la primera parte de esta tesis hemos evaluado el efecto de las condiciones 
fisiológicas del trato urinario sobre la actividad de ciprofloxacino sobre cepas con las 
mutaciones que confieren bajo nivel de resistencia a quinolonas más comunes. Todas las 
cepas que portaban mecanismos cromosómicos y plasmídicos de bajo nivel de resistencia se 
convertían en resistentes a ciprofloxacino bajo las citadas condiciones. Nuestros datos 
sugieren que los métodos recomendados para el estudio de sensibilidad parecen ser un 
estimador pobre de la actividad de ciprofloxacino frente a cepas de E. coli con mecanismos 
de bajo nivel de resistencia en ITUs, sobreestimando su actividad, particularmente en 
pacientes con orina con pH ácido. 
En la última sección, hemos evaluado el efecto de las condiciones fisiológicas del 
tracto urinario sobre la actividad de fosfomicina. Para ello utilizamos cepas de E. coli 
portadoras de distintas mutaciones en genes que confieren resistencia a fosfomicina. 
Nuestros resultados muestran que los métodos estándar para estudiar la sensibilidad frente a 
fosfomicina pueden sobreestimar su efecto, principalmente en pacientes con valores de pH 
en orina elevados.   
  
 
  
Summary  
Urinary tract infections (UTIs) are among the most common bacterial infections 
acquired in the community and in the hospital. During the last years increasing rates of 
antibiotic resistance and high recurrence rates have been described in patients with UTI, 
which have impacted on morbidity and mortality rates and have increased hospitalization 
costs worldwide. In order to rise to this challenge we must understand the evolutionary 
pathways that give rise to resistance during UTI treatments. The goal of this thesis was to 
evaluate the impact of urinary tract physiological conditions on ciprofloxacin and 
fosfomycin activity against Escherichia coli.  
In the first part of this thesis, we have evaluated the impact of the urinary tract 
physiological conditions on the antimicrobial activity of ciprofloxacin against low-level 
quinolone-resistant (LLQR) strains carrying the most frequent chromosomal mutations. Our 
results demonstrate that all the LLQR strains studied became resistant to ciprofloxacin 
under physiological conditions.  Subsequently, we demonstrate that under specific urinary 
tract physiological conditions, susceptible laboratory and clinical strains harboring qnr 
determinants become fully resistant to ciprofloxacin. Thus, our data strongly suggest that 
recommended methods for MIC determination produce poor estimations of CIP activity 
against LLQR E. coli in UTIs, overestimating its activity, mainly in patients with acidic 
urine pH. 
In the last section, the effect of physiological UTI conditions on fosfomycin activity 
was evaluated. With this purpose, we used E. coli strains harboring low-level fosfomycin 
resistance (LLFR) mutations. We demonstrate that standard susceptibility testing in 
Mueller-Hinton with G6P could overestimate the effect of fosfomycin, mainly in patients 
with basic urine pH values. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
‘The thoughtless person playing with penicillin 
treatment is morally responsible for the death of 
the man who succumbs to infection with the 
penicillin-resistant organism’ 
 –Sr. Alexander Fleming, 1945.  
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3.1. Urinary Tract Infection 
 
Urinary tract infections (UTIs) are among the most common bacterial infections 
in humans, representing the second most frequent community-acquired infection in 
women 
1,2
. It is estimated that 50% of women have at least one symptomatic UTI 
episode during their lifetime, and between 20-30% suffer recurrent episodes 
2
. Studies 
suggest that up to 95% of all UTIs are due to an ascending route of infection 
3
. Women 
are more susceptible to UTI than men because their urethral opening is close to the 
vaginal cavity and rectum, facilitating the movement of bacteria from these sites into the 
urethra. 
4
. Furthermore, the shorter distance from the urethral meatus to the bladder 
makes it easier for bacterial to reach the bladder by progressive ascending    
colonization 
5
. Although a higher prevalence of UTI is associated with young women, 
UTI epidemiology depends on the period of life. UTIs occur more often in male than 
female neonates, whereas an almost equal proportion during infancy and young 
childhood is found 
6
. Regarding elderly population, the frequency of male UTI increases 
with age, probably secondary as a side-effect associated with voiding problems 
7
. 
UTIs are classified as either lower (confined to the bladder) or upper 
(pyelonephritis), and as either uncomplicated or complicated 
4
. Uncomplicated UTIs 
affect healthy individuals without structural or neurological urinary tract     
abnormalities 
8
. Complicated UTIs are defined as UTIs associated with factors that 
compromise the urinary tract or the immune status of patients: pregnancy, urinary 
obstruction; urinary retention; presence of foreign bodies (catheters or drainage 
devices); renal failure; renal transplantation or immunosuppression 
9
. This distinction 
has been used to guide the selection and duration of antimicrobial treatments, with 
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broader-spectrum agents and longer courses often recommended for patients with 
complicated UTIs 
5
. 
Regarding the etiology of UTIs, the bacteriology is very predictable: although a 
high number of species can cause UTIs in humans, the majority of infections in all 
populations are caused by the Gram-negative, facultative anaerobic, Escherichia coli 
4
.  
3.1.1. Uropathogenic Escherichia coli  
 
Uropathogenic Escherichia coli (UPEC) are a heterogeneous group within the 
classification of extraintestinal pathogenic E. coli strains 
10
. These bacteria are the 
primary cause of community-acquired UTI (>80%) and a large portion of nosocomial 
urinary infections (>50%), accounting for substantial medical costs and morbidity 
worldwide 
2
. In general, UPEC strains differ from commensal E. coli strains in that the 
former possess additional genetic material, often on pathogenicity associated islands, 
which code for gene products that may contribute to bacterial pathogenesis 
11
. Some of 
these genes allow UPEC strains to express a battery of virulence factors that are 
proposed to play a role in their ability to cause disease, including fimbriae, adhesins, 
toxins, flagella, autotransporter proteins and iron-acquisition systems 
12
. The ascension 
of the urinary tract is mediated by the action of flagella, propelling up UPEC strains 
from the urethra to the bladder.  
Once in the bladder, UPEC strains are able to form intracellular bacterial 
communities (IBC), which protect them from neutrophils, antibiotics and other stresses 
9
. Figure 1 shows the pathogenic cycle of UPEC infection within the bladder. The first 
step is the attachment of UPEC strains to the urothelium through the binding of UPEC 
peritrichous filamentous adhesive organelles (known as type 1 pili or fimbriae) to a 
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variety of mannose-containing glyco-protein receptors in the bladder cells 
13
. After 
adhesion UPEC is initially transferred into membrane-bound compartments that are 
similar to late endosomes 
14
. Then, bacteria replicate and form large biofilm-like 
communities. During IBC maturation, a subpopulation of UPEC progresses into a 
distinct developmental phase in which cell septation is inhibited, which leads to the 
formation of filamentous bacteria 
15
. Eventually, the integrity of the infected cells is 
compromised, and bacteria begin to spill out into urine. The emergent bacteria are often 
highly motile and infect adjacent cells or, eventually, can be flushed out of the urinary 
tract with the flow of urine 
16
. 
 
Figure 1. Pathogenic pathway of UPEC during UTI. Figure adapted from 
17
. 
Considering that antibiotic treatment is our primary, and in many cases only, 
method of treating UTIs caused by UPEC, it is essential to determine the best treatment 
in order to eradicate the infection, preventing the emergence of antimicrobial resistance 
and the risk of recurrence.  
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  3.2. UTI treatment and antimicrobial resistance 
There is general agreement that all symptomatic UTIs should be treated 
1
. In the 
absence of antibiotic therapy, up to 60% of women experience symptoms and/or 
bacteriuria after initial infection 
18–20
, implying that cystitis is not always self-limiting
21
. 
Furthermore, if the infection persists without adequate treatment, in some cases bacteria 
ascend through the ureters, causing pyelonephritis and sepsis 
22
. For this reason, patients 
suffering from UTI are commonly treated with antibiotics. In this way,  antibiotic 
therapy should be individualized based on patient circumstances (allergy, tolerability, 
compliance) 
5
, spectrum and susceptibility patterns of the aetiological uropathogens, 
adverse ecological effects, cost and availability 
23
.  
Recently the Infectious Diseases Society of America and the European Society 
for Microbiology and Infectious Diseases updated clinical practice guidelines for the 
treatment of uncomplicated cystitis and pyelonephritis 
24
. The guideline panel, based in 
the study published by Peterson DL 
25
, suggest that the risk of collateral antibiotic 
damage should be given equal weight as antibiotic efficacy in treatment 
recommendations. According to this premise, the guideline panel listed four oral 
antimicrobials for first-line empiric treatment of uncomplicated cystitis: fosfomycin-
trometamol (3g p.o. in one dose); nitrofurantoin monohydrate/macrocystals (100 mg 
twice daily for 5 days); trimetropin-sulfometoxazol (160/800 mg twice daily for 3 
days); or pivmecillanam (400 mg orally twice daily for 5 days). As second-line 
treatments, the guideline recommends ciprofloxacin (250 mg twice daily for 3 days), 
levofloxacin (250-500 mg once daily for 3 days) and β-lactams (amoxicillin-
clavulanate, cefdinir or cefaclor for 3-7 days). Fluoroquinolones are the only oral 
antimicrobials recommended for empiric treatment of uncomplicated pyelonephritis in 
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outpatients 
24
. Non-hospitalized patients should receive either oral ciprofloxacin (500 
mg twice daily for 7 days or 1000 mg extended release daily for 7 days) or levofloxacin 
(750 mg once daily for 5 days), with this oral treatment preceded by an intravenous 
antimicrobial treatment such as ceftriaxone or a consolidated 24h dose of an 
aminoglycoside. Complicated UTIs are associated with a wide range of clinical 
syndromes and bacteria including multidrug-resistance, making it difficult to generalize 
regarding treatment choice 
26
. Most clinical trials have evaluated 7–14 days of treatment 
27
, with a 3 day course not sufficient for eradicating infection 
28
. Ten to fourteen days of 
antibiotics are usually recommended for patients with pyelonephritis, bacteraemia, 
hypotension and other signs of severe sepsis, whereas a 7 days regimen should adequate 
for lower UTIs 
27,29
.  
It is important to remark that antibiotic use is a key driver of the increase and 
spread of antibiotic resistance 
30,31
. Although there is evidence that antibiotic-resistant 
bacteria existed prior to clinical use of antibiotics, clinical use of these agents has 
certainly been coupled with an increase in the emergence of antibiotic-resistant bacteria 
32
. When antibiotics are prescribed, the primary aim is to achieve the highest non-toxic 
antibiotic concentration in the urinary tract in order to obtain the highest bacterial 
elimination rate, thus preventing the development of resistant strains 
33
. Nevertheless, 
many treatments fall short of this objective due to suboptimal dosing regimens, poor 
drug distribution or penetration, poor patient compliance with taking medication, or low 
antibiotic-activity in the urinary tract 
33
. Lawrenson and colleagues proved that 
whichever antibiotic is prescribed to treat UTI, between 12-16% of the patients returned 
within 28 days for a further course of antibiotic treatment, with women, pregnant 
patients and patients with diabetes significantly more likely to require additional 
treatment 
34
. Moreover, UPEC strains exhibit a high recurrence rate. More than 68% of 
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recurring UTIs are caused by the original E. coli strain, persisting more than 1 year after 
the initial infection 35,36. It is widely thought that recurrences occur through re-ascension 
and re-inoculation of the bladder lumen by an UPEC strain that has persisted in the 
periurethral or fecal flora 
37
. 
 Clinical situations where bacteria are exposed to low levels of antibiotics are 
related with acquisition of antibiotic resistance among UPECs. This situation increases 
the risk of treatment failure due to the use of an ineffective antibiotic, increasing the 
time from an initial diagnosis to an effective therapy, and thus increasing morbidity by 
the use of more toxic antibiotics as subsitutes of those that became ineffective 
38
. 
3.2.1. Low-level resistance 
Antibiotics have collateral effects on the normal microbiota of the vagina and 
gastrointestinal tract, altering its composition and generating a selective pressure 
leading to development of resistant microorganism selection, particularly when the 
treatment is of long duration 
9
. A critical step during antibiotic resistance development 
is the presence of strains with slightly higher antibiotic resistance than is common for 
the susceptible population, but still below the clinical breakpoint 
39
. These strains are 
named low-level resistant (LLR), and are considered and intermediary stage in the 
development of high-resistant strains. LLR appears to facilitate the selections of fully 
resistant strains, allowing bacterial growth at clinical relevant concentrations. The 
importance of these strains is that the LLR phenotype may not be detectable by standard 
susceptibility testing procedures, being classified as “susceptible” although they carry 
genetic determinants that reduce the susceptibility to antibiotics 
39
. Therefore, LLR 
mutants are arguably the first step on the evolutionary pathway to producing high-level 
Introduction 
 
17 
 
resistance, and consequently their dissemination and evolution might influence the 
outcome of antibiotic treatment of UTIs. 
3.2.2. Urinary tract physiological conditions and LLR 
The antibiotic effectiveness for the treatment of UTI not only depends on the 
susceptibility of pathogens and the appropriate antibiotic distribution in bladder and 
kidneys. Physicochemical and pharmacological properties of antibiotics are important 
factors related to successful therapy. Therefore, even if an UPEC strain was susceptible 
and the antibiotic concentration in bladder was optimal, there are several factors in the 
urinary tract that may compromise the efficacy of antimicrobials, contributing to the 
survival of a significant number of microorganisms under these conditions. This 
situation may be enhanced by the presence of LLR mutants, which not only may survive 
under UTI conditions, but also acquire resistance under antibiotic selective pressures 
(Figure 2). 
Urine is a fluctuating and complex fluid composed of over 95% water, plus 
sodium, ammonia, phosphate, sulfate, urea, creatinine, proteins, and products processed 
by the kidney and liver 
40
. Urine is thought to be a primary defense mechanisms due to 
its high osmolality, low pH values and the presence of high concentration of urea that 
can inhibit bacterial growth. However, UPEC strains are able to grow under these 
conditions throught efficient use of the available resources 
11
. Factors associated with 
urine, including calcium and magnesium ion concentrations, have previously been 
shown to affect the outcome of antibiotic susceptibility testing results 
41
. The urinary pH 
level also may affect the antibacterial activity of many therapeutic agents used for the 
treatment of UTIs. The normal range of urinary pH was previously reported to be as 
variable as 4.5 to 8.5 
42,43
. In the study performed by So and colleagues 
44
, most of urine 
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samples collected from patients with UTI  had a pH of 6.5 or lower, which means that 
antibiotics prescribed for UTIs have to be active under acidic conditions in order to 
optimally eradicate the infection.  
Additionally, the bladder environment is mainly anaerobic during UTI. The 
oxygen partial pressure in the urine of healthy patients is estimated to be as low as 25-
80  mmHg 
45
, which is directly related with renal metabolic state. However, in patients 
with urinary infections, the urine oxygen concentration is significantly diminished due 
to the oxygen consumption by the infecting microbes 
46
. Bactericidal antibiotics have 
been shown to kill bacteria (at least in part) by inducing the production of intracellular 
damaging reactive oxygen species (ROS) 
47,48
. Although in a number of recent works 
the role of ROS in the lethal effect of bactericidal antibiotics has been questioned 
49,50
, 
ROS are currently considered a critical factor in antibiotic-mediated killing 
51
. A recent 
study found that killing efficacy of aminoglycosides, fluoroquinolones and β-lactam 
antibiotics was significantly diminished under anaerobic conditions 
47
.  
It is known how urinary tract physiological conditions (changes on pH values, 
urine compounds and anaerobiosis) might compromise the optimal activity of different 
antibiotics. However the knowledge about how UTI conditions could contribute to the 
therapeutic failure against LLR mutants is limited. We hypothesized that, due to the 
reduction of antibiotic activity under these conditions, E. coli strains could be exposed 
to sub-inhibitory antibiotic concentrations, which inhibit bacterial growth but do not kill 
them. Then, a non-lethal selection may results in the emergence of a broader range of 
mutant variants, most of which will individually have small phenotypic effects and low 
fitness cost 
33,52
, giving rise to the presence of high-level resistant microorganism 
populations which are able to produce a new infection (Figure 2).   
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Figure 2. Antibiotic activity and selection for fully resistant (R) and LLR bacteria. A) Bacterial 
population with a subset of resistant organisms. In the presence of an antibiotic, susceptible (S) 
strains are killed, while resistant strains survive, proliferating and causing a new infection. B) 
Bacterial population with a subset of LLR organisms. In this case, the population is susceptible 
to the antibiotic, and the infection is resolved. C) Bacterial population with a subset of LLR 
organisms in the presence of UTI conditions. Under these conditions antibiotic activity could be 
reduced, allowing LLR strains not only to survive but also to acquire resistance under antibiotic 
selective pressures. D) In this case, UTI conditions could increase antibiotic activity, allowing 
the resolution the infection, even in the presence of R bacteria. Figure adapted from 53. 
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3.3. Ciprofloxacin treatment in UTIs  
Quinolones are molecules structurally derived from the heterobicyclic aromatic 
compound quinoline, originated from a substance obtained after the alkaline distillation 
of quinine 
54
. The discovery of nalidixic acid in 1962 by Lesher and associates 
55
 
marked the beginning of five decades of quinolone development 
56
. Since then, all 
current quinolone derivatives have a dual ring structure with a nitrogen at position 1, a 
carbonyl group at position 4, and a carboxyl group attached to the carbon a the 3 
position of the firs ring 
1
 (Figure 3). The potency of quinolones against gram-negative 
bacteria was significantly improved by the development of fluoroquinolones (with the 
addition of a 6-fluoro group) extending the therapeutic spectra and enhancing 
pharmacokinetic properties 
57
. 
 
Figure 3. Chemical structures of quinoline (A), nalidixic acid (B), and ciprofloxacin (C). 
The fluoroquinolone ciprofloxacin is one of most commonly used agents for UTI 
treatment 
58–60
. It has been employed as an appropriate therapy in patients with UTI not 
requiring hospitalization in areas where the prevalence of resistance is under 10%. In 
addition, it is considered an effective treatment in the prevention of UTI in kidney 
transplant recipients 
24,61
. Furthermore, ciprofloxacin shows an excellent bioavailability 
(over the 70% of the administered dose) 
62–64
, particularly due to the high absorption, 
localized preferentially at the duodeno and jejunal level, where it is usually absorbed by 
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passive diffusion 
65,66
. High concentrations of ciprofloxacin (up to 990 mg/L) 
67
 are 
reached in urine during oral treatment of UTIs.  
Ciprofloxacin is highly effective when given as brief courses of 3-10 days, with 
efficacy comparable to trimethroprim-sulfamethoxazole 
68
, nitrofurantoine 
69
, and better 
than amoxicillin-clavulanate 
70
. In comparison with other fluoroquinolones, 
ciprofloxacin shows comparable clinical efficacy and bacteriologic eradication rates to 
levofloxacin 
71
, ofloxacin 
72
, sparfloxacin 
73
 or gatifloxacin 
74
 for UTI treatments. 
3.3.1 Mechanisms of action of fluoroquinolones 
Fluoroquinolones inhibit the enzymatic activities of two members of the 
topoisomerase class of enzymes: DNA gyrase and topoisomerase IV. DNA gyrase, the 
first-recognized target of quinolones, is composed of two A and two B subunits, 
products of the gyrA and gyrB genes, respectively 
75
. DNA gyrase catalyzes the 
introduction of negative superhelical twists into closed covalently circular DNA, and is 
also responsible for removing positive superhelical twists that accumulate ahead of the 
DNA replication fork 
1
. Topoisomerase IV is composed of two subunits encoded by 
parC and parE. The main role of topoisomerase IV seems to be associated with 
decatenating the daughter replicons 
76
. Topoisomerases twist and untwist the DNA helix 
by binding to it and introducing a pair of staggered, single-strand breaks in one 
segment, through which a second DNA segment is passed 
77
. 
When a fluoroquinolone is present, the complex DNA-topoisomerase is altered 
into a drug–enzyme–DNA complex known as a ternary complex, in which the 
topoisomerase is trapped with the bound DNA 
78
. Fluoroquinolones bind to DNA gyrase 
or topoisomerase IV, which is then unable to re-ligate the DNA substrate 
79
, thereby 
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converting the enzyme-DNA complex into a poisonous complex 
80
. The broken 
segments of DNA bound to the enzyme are named as “cleaved complexes”. If the level 
of topoisomerase-mediated DNA cleavage becomes too high, the action of DNA 
tracking systems can convert these transient complexes to permanent double-stranded 
breaks 
81
. They interact with DNA and the GyrA subunit of the DNA gyrase, or the 
ParC subunit of the topoisomerase IV, stabilizing the DNA-enzyme cleavage complex, 
and leading to the blockage of the replication machinery progression, DNA lesions 
formation, and finally to bacterial death 
82
. 
 
Figure 4. Ternary complex formed between DNA, DNA–gyrase/topoisomerase IV -and stacked 
fluoroquinolone. The binding site for fluoroquinolones is located in the bubble formed during 
the local opening of the DNA molecule. The right panel shows the sites of the antibiotic 
molecules which interact with DNA, with the enzyme, or favoring the stacking of the 
fluoroquinolone molecules. Adapted from Bambeke et al. 83. 
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3.3.2. Fluoroquinolone resistance in E. coli 
During recent years, an increase in resistance to fluoroquinolones in E. coli 
strains has been described worldwide 
84
. As mentioned above, the prevalence of 
antibiotic resistant strains has been related with antibiotic use 
85
. The European Centre 
for Disease Prevention and Control (ECDC) provides information about antibiotic 
consumption and the rates of resistance in E. coli strains from all the countries of the 
European Union. Figure 5 illustrates fluoroquinolone consumption in defined daily dose 
(DDD) per 1000 patients per day and rates of resistance to fluoroquinolones in invasive 
E. coli strains from 2001 to 2015 in Spain. It can be observed that the progressive 
increase of resistant E. coli strains appears to be related with antibiotic consumption, 
reaching resistance rates over 34%.  
Furthermore, several clinical factors have been considered as possible predictors 
of fluoroquinolone resistance. Colodner and colleagues found that previous invasive 
procedures (like urine catheters, foreign bodies, orthopedic devices, etc.), recurrent UTI 
and previous hospitalization were independent risk factors for community-acquired UTI 
caused by quinolone resistant E. coli strains 
86
. The presence of complicated UTI 
87,88
, 
urinary catheterization in the previous 6 months 
59,89
 and male gender 
90
 have been 
identified as predictor factors of quinolone resistance in UTI. Increasing age was also 
associated with an increased risk of UTI by quinolone resistant UPEC, with relatively 
low resistance rates among UPEC isolates from pediatric outpatients (5.1%), higher 
among isolates from adult outpatients (11.8%), and the highest among isolates from 
older adult outpatients (29.1%) 
91
. 
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Figure 5. Fluoroquinolone usage and resistance rates in Spain from 2001 to 2015. This graph 
represents percentage of fluoroquinolone resistant Escherichia coli isolates (red bars) and 
fluoroquinolone consumption in defined daily dose (DDD) per 1000 patients per day           
(blue area chart) in the community. Data from http://ecdc.europa.eu 
 
3.3.3. Fluoroquinolone resistance mechanisms in E. coli 
3.3.3.1. Chromosomal-mediated quinolone-resistance  
Quinolone resistance is principally acquired through mutations in the genes 
encoding gyrase and topoisomerase 
92
. Target alterations due to mutations in the gyrA, 
gyrB, parC, and parE genes have been described in UPEC, most of which are located in 
small regions of either gyrA or parC, known as the quinolone resistance-determining 
region 
93,94
. These chromosomal mediated quinolone-resistance (CMQR) mutations are 
commonly situated in the amino terminal domains of GyrA (residues 67 to 106 for E. 
coli numbering) or ParC (residues 63–102) 95. The most common mutation observed in 
clinical isolates is at codon 83 (S83L) in gyrA, followed by codon 87 (D87 to N, Y, G, 
or H) 
96–98
. In ParC, the common substitutions appear to be at codons 80 and/or 84 
97
. 
Mutations in specific domains of GyrB and ParE have also been shown to cause 
quinolone resistance, although they are substantially less common in resistant UPEC 
isolates. The study performed by Lindgren and colleagues 
98
 found mutations in parE 
Introduction 
 
25 
 
gene in 5 from 54 strains (9.25%), four of them accompanied with mutations in gyrA 
and parC. Similar results were obtained by Takahashi and colleagues 
99
, where 18 from 
178 strains (10.11%) presented mutations in the parE gene.  
3.3.3.2. Efflux pumps and porins 
Efflux pumps in E. coli have a broad substrate range and transport antibiotics out 
of the bacterium, conferring intrinsic multidrug resistance 
100
. Genes encoding these 
efflux pumps are classified into the following five superfamilies: the major facilitator 
superfamily (MFS), small multidrug resistance (SMR), multidrug and toxic compound 
extrusion (MATE), ATP-binding cassette (ABC), and resistance-nodulation-cell 
division (RND) 
101
. Among RND transporters of E. coli, only the AcrB-AcrA-TolC 
complex (also called AcrBA-TolC) is constitutively expressed and plays a major role in 
multidrug resistance. It is composed of the inner membrane RND antiporter AcrB that 
functions in a tripartite assembly with a periplasmic adaptor protein, AcrA, and the 
outer membrane channel, TolC 
100,102
. Inactivation of AcrB increases the susceptibility 
of laboratory mutants of E. coli and other Enterobacteriaceae to many antimicrobials, 
whereas over-expression confers resistance to multiple drugs, including      
ciprofloxacin 
103
. Moreover, mutations in acrR (a repressor of acrAB) increase pump 
activity 
104
. The MarR protein, which regulates expression of marA, is expressed from 
the MAR (from multiple antibiotic resistance) operon, regulating the transcription of 
acrAB and tolC genes 
105
. Thus, inactivation of the repressor MarR increases the 
expression of marA, which amplifies the transcription of the pump genes acrAB and 
tolC, increasing the efflux of ciprofloxacin 
106
.  
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Three main porins are located in the outer membrane of E. coli: OmpA, OmpC 
and OmpF 
76
. Alterations in membrane permeability are usually associated with 
decreased expression of these porins 
107
. Both OmpF and OmpC channels are 
homotrimers, and in each monomer 16 β-strands span the outer membrane to form a 
barrel 
108
. Genes enconding OmpF and OmpC (ompF and ompC) are transcriptionally 
regulated, depending on the temperature and the osmolarity of the media, by the two-
component regulatory system OmpR-EnvZ that mediates both positive and negative 
control 
109
. There is also a post-transcriptional control by the small regulatory RNA 
molecules, micC and micF, which downregulate OmpC and OmpF expression 
respectively 
110,111
. Furthermore, MarA induce upregulation of an antisense micF, 
causing a significant reduction in expression of ompF 
109
. The porine OmpF facilitates 
the diffusion of fluorinated quinolones such as ciprofloxacin and cephalosporins into the 
periplasm, with marked reductions in accumulation of these agents in the OmpF-
deficient bacterial strains. In this way, down-regulation of these porins as well as point 
mutations can lead to reduced accumulation of quinolones (and other agents) within the 
bacterial cell 
112
. The OmpC channel is smaller than that of OmpF, and for this reason 
antibiotic molecules with large side chains are more restricted in their permeation 
through OmpC than through the wider OmpF channel 
113
. 
3.3.3.3. Plasmid-mediated quinolone-resistance 
Recently several plasmid-mediated quinolone-resistance (PMQR) mechanisms 
have been identified. The first report of a plasmid-mediated quinolone resistance 
describes the presence of a 218 aminoacid protein termed Qnr, that protects DNA from 
quinolone binding to topoisomerases 
114
. Since then, five groups of plasmidic Qnr 
determinants (encoded by the genes qnrA, qnrB, qnrC, qnrD and qnrS) have been 
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described 
115
. The qnrVC gene from Vibrio cholerae can also be located in a plasmid 
116,117
 or in transmissible form as part of an integrating conjugative element 
118
. These 
qnr genes generally differ in sequence by 35% or more from qnrA and each other 
119
. 
Allelic variants have also been described in each family, differing by 10% or less: 5 
alleles for qnrVC, 7 alleles for qnrA, 9 for qnrS, and 71 for qnrB 
120
. Qnr proteins 
appear to bind to gyrase and topoisomerase IV targets in such a way as to destabilize the 
cleavage complex enzyme-DNA-quinolone, beginning quinolone release, religation of 
DNA, and regeneration of active topoisomerase. Moreover, QnrA, QnrB and QnrS have 
been shown to protect DNA gyrase from quinolones in E. coli 
80,121–123
. QnrA also 
protects topoisomerase IV 
80
. Furthermore, qnr genes are often associated with 
extended-spectrum β-lactamases and aminoglycoside resistance encoding genes on the 
same plasmid 
124
, increasing mutually the probability of dissemination 
125
. 
Additionally, three further PMQR genes have been found: i) aac(6’)-Ib-cr is a 
variant aminoglycoside acetyltransferase that reduces ciprofloxacin activity 
126
. This 
enzyme, in addition to aminoglycoside antibiotics, confers resistance to ciprofloxacin 
and norfloxacin by N-acetylation of the amino nitrogen on its piperazinyl substituent 
127,128
; ii) qepA and oqxAB encoding efflux pump 
129,130
. QepA is a plasmid-mediated 
efflux pump of the major facilitator family that decreases susceptibility to hydrophilic 
fluoroquinolones, especially ciprofloxacin, norfloxacin and veterinary enrofloxacin 
129
. 
Concerning oqxAB, it is an efflux pump that was initially recognized on transmissible 
plasmids responsible for resistance to olaquindox 
130,131
. It has a wide substrate 
specificity including chloramphenicol, trimethoprim, and quinolones such as 
ciprofloxacin, norfloxacin, and nalidixic acid 
132
. 
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3.3.3.4. Low-level quinolone-resistance 
Resistance to fluoroquinolones is a step-by-step phenomenon involving 
accumulation of resistance mechanisms. The presence of single chromosomal mutations 
in gyrA or parC, as well as the presence of PMQR genes, lead to generation of low-
level quinolone resistant (LLQR) strains, with fluoroquinolone MICs that are higher 
than the epidemiological cutoff value but still below the resistance breakpoint for most 
fluoroquinolones. A high prevalence of LLQR UPEC mutants in UTIs has been 
described. Takahashi and colleagues analyzed CMQR genes in 89 fluoroquinolone-
susceptible UPEC strains from patients with complicated or uncomplicated cystitis, 
finding that 16 (17.97%) of these strains were LLQR mutants 
99
. Lindgren and 
colleagues studied 53 strains with susceptibilities that covered the full range of MICs 
and that were isolated from patients with uncomplicated UTIs, concluding that at least 
17 strains (70.91%) from fluoroquinolone-susceptible strains presented CMQR 
mutations 
98
. Additionally, a high prevalence of qnr genes has been found in clinical 
urinary isolates (from 10.81% to 31.6%)
133–135
. This prevalence varies depending on 
geographical location, patient characteristics (e.g. higher prevalence in inpatients than 
outpatients) 
133
 or associated antibiotic susceptibility patterns 
135,136
. 
It should be noted that the causes of this high prevalence of LLQR among UTI 
isolates remain puzzling: these mutations and PMQR determinants only lead to a slight 
increase in resistance (below the clinical breakpoint) that should not be enough to 
survive under the extremely high quinolone concentrations attained in the urinary tract. 
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3.3.3.5. Effect of urinary tract physiological conditions on              
ciprofloxacin activity  
The effectiveness of ciprofloxacin for the treatment of UTI does not only depend 
on pathogen susceptibility. It has been emphasized that physicochemical proprieties of 
quinolones have major consequences for their pharmacokinetics and pharmacodynamics 
41
. Ciprofloxacin is an ampholyte that can exist in four different pH-dependent 
protonation forms namely cation (H2X
+
), zwitterion (HX
±
), neutral (HX
0
), and anion 
(X
-
) depending on the pH of the medium 
137
. At the isoelectric point of quinolones in 
water (about pH 7), the mole fractions of the zwitterionic and neutral species reach their 
maximum values, being zwitterions the most stable species 
138
. Figure 6 represents 
ciprofloxacin speciation as cation, zwitterion, and/or anion as a function of pH values. 
Antibiotics in zwitterionic forms are optimal for porin permeability, favoring increased 
bacterial accumulation 
139,140
.  
 
Figure 6. Distribution of ciprofloxacin species as a function of pH.  The pKa value given for the 
carboxyl (pKa1) or amino (pKa2) group refers to the equilibrium between the protonated positive 
and deprotonated neutral group. Figure adapted from 
141
. 
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However, as previously mentioned, most patients with UTI caused by E. coli 
present urinary pH values lower than 6.5. At these pH values ciprofloxacin is cationic 
(positively charged), decreasing the penetration into bacteria, and thus, reducing its 
activity 
112,142
. 
In addition to the effect of pH on the activity of ciprofloxacin, there are several 
urine compounds that can interact with ciprofloxacin, reducing its activity. For instance, 
divalent urinary cations may also decrease ciprofloxacin activity 
143
. In this way, the 
cation magnesium (Mg
2+
) interacts with the quinolone carboxyl (COO-) group 
144
, 
generating quinolone-magnesium complexes that are significantly less active than the 
quinolone drugs alone. It has been also found that the activity of quinolones is reduced 
when the solutions are titrated with magnesium ions 
145
. Moreover calcium have also 
been related with impairment of uptake quinolones by bacteria 
146
. 
Another physiological factor that could reduce quinolone susceptibility is the 
absence of oxygen under urinary tract conditions. Higher concentrations of 
ciprofloxacin are needed to kill cells under anaerobic conditions, an observation 
supported by the higher minimal inhibitory concentration (MIC) values found under this 
condition 
147
. Previous works have shown that fluoroquinolones induce physiological 
alterations in the cellular redox state, promoting the formation of reactive species 
including ROS 
47,48
. Under anaerobic conditions, ciprofloxacin activity is significantly 
reduced, but not completely eliminated 
47
, supporting that the availability of molecular 
oxygen plays a significant role for the lethality of quinolones 
148
.  
Despite the fact that the effect of pH, urine and anaerobiosis on ciprofloxacin 
activity has received considerable attention, little is known about how the urinary 
physiological conditions impact ciprofloxacin activity against LLQR mutants. Under 
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these conditions, it is possible that LLQR mutants may be as effective as high-level 
resistant strains, allowing these mutants to survive the clinical concentrations of 
ciprofloxacin in urine. In addition, it has been demonstrated that fluoroquinolones 
increase mutagenesis in bacteria via the induction of SOS error-prone DNA 
polymerases expression, DNA recombination 
149
 and the horizontal transfer of DNA 
sequences 
150–152
. Thus, the effect of UTI conditions on ciprofloxacin activity, together 
with the mutagenesis induction produced by this antibiotic, could give place to ITU 
recurrence by UPEC with a development of a wide spectrum of resistance mechanisms.  
3.4. Fosfomycin treatment in UTIs  
Fosfomycin is a phosphonic acid derivative produced by a broad variety of 
Streptomyces and Pseudomonas species 
153
. This antibiotic contains an epoxide and a 
propyl group (cis-1,2-epoxypropyl phosphoric acid; C3H7PO4), with a unique chemical 
structure (Figure 7) and a very low molecular weight 
154
. Moreover, it is unrelated to 
any other antibiotic family, being a class of its own 
153
. 
 
Figure7. Molecular structure of A) Fosfomycin trometamol;                                                        
B) Fosfomycin calcium; and C) Fosfomycin Disodium 
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 Fosfomycin was initially developed in Europe by the Compañia Española de 
Penicilina y Antibióticos (CEPA) 
155
, and has been used since the early 1970s, initially 
as an intravenous preparation of the disodium salt, and later as an oral formulation of 
fosfomycin trometamol 
156
. Additionally, other formulations like fosfomycin calcium 
for oral use, as well as fosfomycin disodium for intravenous use are also available 
157
. 
Since fosfomycin was discovered in 1969 
155
, this natural antibiotic has attracted 
considerable clinical and scientific interest due to its broad spectrum bactericidal 
activity against Gram-positive and Gram-negative bacteria 
20,158,159
. Furthermore, owing 
to the emergence of multi-drug resistant bacteria as well as the limited options of new 
antibiotic agents, fosfomycin is being reevaluated as a potential therapeutic option, 
being present in numerous clinical guidelines and trials for the treatment of different 
infections 
160–163
. 
Fosfomycin has been widely used as a first-line agent for the empirical treatment 
of UTIs 
154
. Fosfomycin trometamol is the preferred formulation for oral administration 
because it is more readily absorbed compared with other formulations. Moreover, it is 
administered in a single dose, improving compliance, reducing adverse events or 
toxicity, and reducing the effects on the normal microbiota of the vagina and 
gastrointestinal tract 
164
. It is marketed under the brand name Monuril
®
, Monurol
®
 or 
Monural
®
, at a dose of 5.61 g of fosfomycin trometamol, which is equivalent to 
approximately 3 g of pure fosfomycin 
157
. After oral 3-g dose administration, peak urine 
concentrations are reached within 4h, where it is possible to find concentrations of 
1053-4415 μg/ml 165,166. Furthermore, after this treatment, high fosfomycin 
concentrations (>128 μg/ml) persist during 1-2 days in urine and bladder, enough to 
eradicate any susceptible bacteria 
166
. Regarding the efficacy of fosfomycin versus other 
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antibiotics, the meta-analysis of randomized controlled trials performed by Falagas and 
colleagues 
20
 demonstrated that fosfomycin treatment in patients with cystitis was equal 
to the comparator regimens (quinolones, trimethoprim, trimethoprim-sulfamethoxazole, 
β-lactams or nitrofurantoin) in terms of clinical effectiveness and safety profile. 
3.4.1 Mechanisms of action of fosfomycin 
Fosfomycin is a bactericidal antibiotic agent that inhibits an enzyme-catalyzed 
reaction in the first step of the synthesis of the bacterial cell wall 
167
. In E. coli 
fosfomycin is actively transported into bacterial cytoplasm via GlpT and UhpT 
transporters 
168
. The GlpT antiporter is a member of the MFS, which is commonly 
responsible for the import of glycerol-3-phosphate driven by inorganic phosphate 
gradient 
169
. The UhpT is a chemiosmotic transporter that catalyzes the accumulation of 
glucose-6-phosphate (G6P) by exchange with internal inorganic phosphate 
170
. UhpT is 
also a member of the MFS that requires transcriptional activation by the response 
regulators UhpA and UhpB, which together form a two-component regulatory system 
that activates expression of the transporter UhpT 
171
. This activation is produced after 
recognition of extracellular G6P by the constitutively expressed sensor UhpC, which 
interacts with UhpB stimulating its kinase activity 
172
. After that, a phosphate group is 
transferred to UhpA, which acts as a transcriptional activator for the expression of the 
uhpT gene. The expression of both GlpT and UhpT transporters are also regulated by 
cyclic AMP (cAMP) levels in the cell 
173
.  
In E. coli, the expression of the glpT and uhpT genes are activated by the 
complex of cAMP and its receptor termed cAMP receptor protein (CRP) 
174,175
, also 
known as catabolite activator protein (CAP). cAMP synthesis depends on the activity of 
adenyl cyclase CyaA, which is also regulated by the phosphotransferase enzyme PtsI, a 
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component of the phosphoenol-pyruvate sugar phosphotransferase transport system 
153
. 
CRP is one of the main global transcription regulators in E. coli, whose activity is 
triggered by binding of cAMP in response to glucose starvation and other stresses 
176
. 
Additionally, the FNR (fumarate-nitrate reduction) protein is a transcriptional regulator 
containing a Fe-S cluster, serving as a redox sensor, and is active during anaerobic 
growth 
177
. Under this condition, FNR proteins bind to the regions upstream of glpT and 
uhpT, acting as an activator of these genes 
178
. The regulation of glpT and uhpT genes is 
represented in Figure 8. 
 
Figure 8. Regulation of uhpT and glpT gene expression. Figure adapted from 153. 
Once has reached the cytoplasm, fosfomycin acts as a phosphoenolpyruvate 
(PEP) analogue, binding covalently to the thiol group of the Cys115 in the active site of 
MurA (UDP-GlcNAc enolpyruvyl transferase), an essential enzyme for peptidoglycan 
biosynthesis 
168,179
.  
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Nucleophilic attack on the β-carbon of fosfomycin by Cys115 opens the epoxide 
to form an irreversible active site modification that eliminates MurA activity 
173
. Thus, 
fosfomycin disrupts the formation of Enolpyruvate-UDP-N-acetylglucosamine acid 
from UDP-N-acetylglucosamine and phosphoenolpyruvate, which is the initial step in 
peptidoglycan chain formation of the bacterial wall 
168
. 
 
Figure 9. A) Fosfomycin irreversibly modifies MurA by forming a covalent linkage with 
Cys115. B) MurA catalyzes the formation of UDP-N-acetylglucosamine-enolpyruvyl from 
phosphoenolpyruvate and UDP-N-acetylglucosamine. Figure modified from 
173
. 
 
3.4.2. Fosfomycin resistance in E. coli 
The frequency of fosfomycin resistance among UPEC has been recognized to be 
very low 
154,180
. Most of the studies using E. coli strains collected from clinical urine 
samples have revealed high rates of susceptibility, ranging between 95 to 100% 
181–185
. 
The largest of these studies was a multicenter study performed in 20 hospitals in Spain, 
where 99.8% of 2292 E. coli isolates were susceptible to fosfomycin, whereas resistance 
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rates to other antibiotics like ampicillin, ciprofloxacin and cotrimoxazole were 
remarkably higher (52.1%, 18.1%, and 25.2% of isolates, respectively) 
181
.  
During recent years, most of the studies published have evaluated the in vitro 
activity of fosfomycin against extended-spectrum β-lactamases (ESBL) producing 
Enterobacteriaceae, particularly in E. coli 
186–191
. Although the frequency of cross-
resistance of fosfomycin and other antibiotics is expected to be very low because of the 
unique mode of action of this antibiotic 
192
, Oteo and colleagues showed a parallel 
increase in the use of fosfomycin in the community and resistance to fosfomycin in 
ESBL-producing E. coli from UTI in Spain 
193
.  
3.4.3. Fosfomycin resistance mechanisms in E. coli 
3.4.3.1. Chromosomal-mediated fosfomycin-resistance 
The most important mechanism of E. coli resistance to fosfomycin is the 
presence of mutations in genes encoding the uptake systems used for fosfomycin entry 
inside the bacteria 
153,154
. Mutations in any of the structural genes of those pathways 
decrecrease antibiotic uptake, conferring different levels of fosfomycin resistance 
168,194
. 
Strains defective in fosfomycin uptake are not able to grow using some substrates as the 
only carbon source, such as glycerol-3-phosphate in GlpT-deficient strains or G6P (and 
other hexose phosphates) in Uhp-deficient strains 
183
. Mutants affected in both systems 
are often unable to grow using multiple carbohydrates. In this way, it has been observed 
that the addition of G6P induces fosfomycin sensitivity in resistant GlpT-deficient 
strains, due to the induction of UhpT synthesis 
168
. For this reason MIC determinations 
of fosfomycin are performed with media containing G6P.  
Introduction 
 
37 
 
As mentioned above, cAMP is required for the full expression of the fosfomycin 
transporters GlpT and UhpT. Mutations in cyaA or ptsI produce a decrease in the 
intracellular cAMP levels and, subsequently, a reduced expression of both fosfomycin 
transporters, leading to diminished antibiotic uptake 
153,183
. Furthermore, inactivation of 
the cAMP receptor protein CRP affects the expression of both transport systems, 
decreasing the susceptibility to fosfomycin. cAMP-CRP recognizes several binding 
sites upstream of the glpTQ operon 
195,196
, upregulating the expression of glpT. The 
complex cAMP-CRP also binds to the uhpT promoter at a single site upstream of the 
UhpA-binding sites, stabilizing the open promoter complexes for uhpT transcription, 
increasing the rate of their formation 
175,197
. Although the role of CRP in glpT and uhpT 
expression is well known, there is currently a lack of information about how mutations 
in the crp gene could affect fosfomycin susceptibility in E. coli clinical isolates.  
Fosfomycin resistance by target modification has also been described. Kim and 
colleagues 
198
 demonstrated that substitution of Cys 115 by Asp (C115D) retain MurA 
activity and confer high-resistance to fosfomycin. However, few reports of clinical 
isolates shown mutations in the murA gene, and none in the catalytic site of MurA, 
because most of them reduce drastically bacterial cell viability 
199
. However, 
overexpression of the murA gene in E. coli have been correlated with higher levels of 
fosfomycin resistance, reaching clinical resistance levels at a low fitness cost 
200
. 
3.4.3.2. Plasmid-mediated fosfomycin-resistance 
The transfer of a fosfomycin resistance marker encoded by a plasmid by 
conjugation was described in 1980 in Serratia marcesens 
201
. Since then, several 
enzymes able to modify fosfomycin have been described, producing chemical changes 
that inactivate it. Microbial resistance to fosfomycin by antibiotic modification 
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transmited by plamids involves five different fosfomycin resistance proteins: FosA 
202
, 
FosB 
203
, FosC 
204
, FosK 
205
 and FosX 
206
.  
FosA (glutathione S-transferase) is a metalloenzyme transferred through 
plasmids in Enterobacteriaceae first described in 1988 
202
. FosA-class are 
metalloenzymes that catalyze the nucleophilic addition of the tripeptide glutathione to 
the fosfomycin C1 position, cleaving the epoxide ring and inactivating the antibiotic 
207–
209
. New subtypes, with similar structure, of the gene have been described 
154
. FosA3 is 
the most prevalent enzyme isolated in E. coli clinical isolates, with an aminoacid 
homology of 80% with FosA 
210
. FosA4 is a newly identified variant of FosA3, sharing 
94% of aminoacid identity that has been recently described in E. coli 
211
. The fosA5 
gene encodes a 139-amino-acid protein that shares 70 and 73% identity with FosA and 
FosA3, respectively 
212(p5)
. Another FosA subtype, named fosKP96, has also been 
described in two E. coli strains from blood and urine infections, although there is little 
information about its activity and identity rates with other FosA enzymes 
213
. Co-
occurrence of FosA and FosA3 subtypes in plasmids with severeal antibiotic resistance 
genes have been reported, conferring resistance to β-lactams, quinolones, 
aminoglycosides, macrolides, sulfonamides, and tetracyclines 
186,214–216
. The genes 
conferring resistance to fosfomycin could be transferred together with genes conferring 
resistance to other antibiotics in either the same or a conjugate plasmid 
154
. 
The presence of FosC2 in E. coli have been recently described in Japan 
210
. The 
amino acid sequence of FosC2 had 72% identity to that of FosC found in 
Achromobacter xylosoxidans. However, the prevalence of FosC2 in E. coli clinical 
strains remains unclear.  
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3.4.3.3. Low-level fosfomycin resistance: 
The steps by which fosfomycin-resistant E. coli mutants arise and spread during 
UTI is not well known. As previously mentioned, fosfomycin resistance has been 
associated with chromosomal mutations in genes related to the fosfomycin target 
(murA) or to fosfomycin intake (glpT, uhpA, uhpT, cyaA or ptsI). However, there are 
very few studies that provide information about the prevalence of these mutations in 
UPEC, as well as the contribution of each mutation to fosfomycin resistance.  
Ballestero-Téllez and colleagues 
217
 have recently published that the presence of 
single chromosomal mutations, or even in selected combinations, are related with 
increases in fosfomycin MICs, but not conferring clinical resistance according to 
international guidelines. However, although the presence of low-level fosfomycin 
resistance (LLFR) mutants yields a fosfomycin-susceptible phenotype, they may 
facilitate the selection of highly resistant subpopulations when additional mutations 
appear. There are only two studies where LLFR in E. coli clinical strains have been 
evaluated 
183,192
. Nilsson and colleagues studied 13 clinical strains, seven of them 
showing reduced fosfomycin susceptibility (MIC ≥8μg/mL), but still considered as 
susceptible to fosfomycin (MIC ≤64). Ohkoshi and colleagues studied 211 E. coli 
clinical strains, where seven were LLFR. These strains showed several mutations in one 
or more genes (uhpT, glpT, cyaA and ptsI) leading to amino acid deletions or changes of 
amino acid residues, compared with other susceptible strains. However, it is unclear 
whether these mutations contributed to the reduced susceptibility.  
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3.4.3.4. Effect of urinary tract physiological conditions on fosfomycin activity 
Conversely, the effect of urinary tract physiological conditions on fosfomycin 
activity has not been studied as well as ciprofloxacin. Hence, there is no previous 
evidence concerning the effect of urine compounds on fosfomycin activity. Regarding 
the effect of pH, the activity of fosfomycin increases at acidic pH values 
142,218,219
, with 
the greatest activity observed at pH 5.5 
220,221
. However, the molecular basis of this 
effect is obscure. It has been shown that acidic environments decrease cAMP levels into 
bacterial cytosol 
222
, and consequently, the expression of the fosfomycin transporters 
GlpT and UhpT are reduced. For this reason, fosfomycin activity should be reduced 
under acidic pH values, but the reality appears to be far different. Recently, Fedrigo and 
colleagues 
223
 evaluated the effect of fosfomycin at pH6 and 7 against E. coli and 
Klebsiella pneumoniae strains. They suggest that at acidic pH values, fosfomycin 
molecules are partially protonated, in a more lipophilic state, that allows the entrance of 
fosfomycin molecules into bacteria, thus resulting in a greater activity.  
The activity of fosfomycin increases under anaerobic conditions 
224
. Unlike urine 
and pH, molecular mechanisms related with fosfomycin activity under anaerobic 
conditions are well understood. The FNR is active under anaerobic conditions, binding 
to the regions upstream of glpT and uhpT, acting as an activator of these genes 
178
. 
Furthermore, a higher expression of crp and cyaA genes has been found in anaerobic 
conditions, increasing, in turn, the expression of glpT and uhpT 
225
. Wherefore, the 
increased antibacterial activity of fosfomycin against E. coli strains under anaerobic 
condition is attributed to an elevated expression of GlpT and UhpT transporters.  
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In the particular case of fosfomycin, it appears that urinary tract physiological 
conditions (low pH values and anaerobiosis) could increase its activity, allowing a good 
effect against LLFR mutants. Nevertheless, it is necessary to know how LLFR mutants 
contribute to fosfomycin-susceptibility and bacterial fitness under UTI conditions. 
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The main objective of this Thesis was to evaluate the impact of urinary tract 
physiological conditions (urine, pH and anaerobiosis) on the antimicrobial activity of 
ciprofloxacin and fosfomycin against E. coli. The research is divided into a series of 
partial objectives that can be summarized as follows: 
1. To study the effect of urinary tract physiological conditions on ciprofloxacin activity 
against a set of well-characterized isogenic LLQR E. coli strains, carrying the most 
frequent chromosomal mutations and PMQR determinants. 
1.1 To evaluate the effect of LLQR mutations on bacterial growth rates under urine 
conditions.  
1.2. To determine the effect of urine, pH and anaerobiosis on ciprofloxacin MIC 
values on well-characterized LLQR isogenic strains.  
1.3. To evaluate the survival rates of these strains in the presence of the maximum 
concentration of ciprofloxacin reached in the bladder.  
1.4. To study the effect of urine, pH and anaerobiosis on ciprofloxacin activity 
against well-characterized LLQR clinical isolates. 
2. To study the effect of urinary tract physiological conditions on fosfomycin activity 
against a set of well-characterized isogenic LLFR and fosfomycin-resistant strains, 
carrying the most frequent chromosomal mutations.  
2.1. To evaluate the effect of LLFR mutations on bacterial growth rates under urine 
conditions.  
 
Objectives 
 
 
 
46 
2.2. To determine the effect of urine, pH and anaerobiosis on fosfomycin MIC 
values on well-characterized LLFR isogenic strains. 
2.3. To study the effect of urine, pH and anaerobiosis on fosfomycin activity against 
well-characterized LLFR and fosfomycin-resistant clinical isolates. 
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‘Results! Why, man, I have gotten a lot of results!  
I know several thousand things that won’t work.’ 
 
-Sir Thomas A. Edison. 
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Publication I: Urinary Tract Physiological Conditions Promote Ciprofloxacin 
Resistance In Low-Level Quinolone Resistant Escherichia coli. 
An increase in resistance to fluoroquinolones has been described worldwide 
during recent years. DNA gyrase and DNA topoisomerase IV, involved in DNA 
supercoiling, are the targets of fluoroquinolones. Gyrase and topoisomerase IV are 
composed of two subunits encoded by the genes gyrA and gyrB, and parC and parE, 
respectively. Ciprofloxacin resistance can be acquired through mutations in these genes 
encoding gyrase and topoisomerase or in genes affecting efflux or permeability of the 
bacteria such as marR or acrR. Typically, single mutations have been associated with 
low-level fluoroquinolone resistance, and accumulation of several mutations develops 
high-level resistance. Some of these mutations confer LLQR with slightly increased 
MICs than is common for the susceptible population, but still under the resistant 
breakpoint. Remarkably, LLQR strains have been suggested to be the first evolutionary 
step for producing high-level of quinolone resistance.  
The main objective of this work was to elucidate the effect of urinary 
physiological conditions on ciprofloxacin activity against E. coli strains carrying LLQR 
mutations. Ciprofloxacin is an ampholyte that can exist in four different pH-dependent 
protonation forms. Thus, depending on the pH, the ionization status of ciprofloxacin 
increases its permeability or improves its intestinal absorption modifying consequently 
its antimicrobial activity. Furthermore the presence of urinary divalent cations and 
anaerobic conditions have been related with a reduction of ciprofloxacin activity. The 
combination of ciprofloxacin activity reduction in the urinary tract and the presence of 
LLQR mutants may lead to a non-lethal selection, where the bacterial growth is 
inhibited but they are not killed. 
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Our results demonstrate that urinary tract physiological conditions reduce 
significantly the effect of ciprofloxacin against E. coli strains with LLQR mutations. 
The presence of urine, low-pH values and anaerobiosis increase the MIC values of 
ciprofloxacin, with all the LLQR mutants becoming clnically resistant strains according 
to international guidelines. Furthermore, the presence of these mutations also facilitates 
high bacterial survival even when we simulate the maximum ciprofloxacin 
concentration reached in urine within the first 6 h after administration of an oral dose of 
500 mg of ciprofloxacin. 
The results presented here raise questions concerning the general applicability of 
the recommended methods for MIC determinations, which appears to be a poor 
estimator of ciprofloxacin activity against LLQR E. coli in UTIs. International 
guidelines for MIC determinations should reconsider clinical breakpoints, taking into 
account the effect of common low pH values in ciprofloxacin activity. 
 
Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-
Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez. Urinary tract 
physiological conditions promote ciprofloxacin resistance in low-level quinolone 
resistant Escherichia coli. Antimicrobial Agents and Chemotherapy 2016, 20: 
60(7):4252-8. 
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Publication II: Plasmidic qnr Genes Confer Clinical Resistance to Ciprofloxacin 
under Urinary Tract Physiological Conditions. 
Taking the previous proposal (Publication I) as a premise, the aim of this work 
was to evaluate the impact of urinary physiological conditions on ciprofloxacin activity 
against E. coli strains harboring plasmidic qnr genes. Plasmid genes qnrA, qnrB, qnrC, 
qnrD, and qnrS code for proteins of the pentapeptide repeat family that protect DNA 
gyrase and topoisomerase IV from quinolone inhibition. The presence of PMQR genes 
lead to generation of LLQR, with fluoroquinolone MICs that are higher than the 
epidemiological cutoff value but still below the resistance breakpoint for most 
fluoroquinolones. 
The qnr genes have apparently to have been acquired from chromosomal genes 
in aquatic bacteria, and are usually associated with mobilizing or transposable elements 
on plasmids. Additionally, qnr genes are often associated with extended-spectrum β-
lactamases and aminoglycoside-resistance genes on the same plasmid, and thus, 
increase the probability of survival after UTI treatment and dissemination. 
The results presented here show how the presence of urine, low-pH values and 
anaerobiosis lead to reduce ciprofloxacin activity, causing an increase of MIC values 
above the cutoff of resistance. Thus, UTI conditions could be an ideal environment for 
the selection of strains harboring qnr genes, allowing the survival of E. coli strains 
considered susceptible to fluoroquinolones. Again, international MIC breakpoints 
appear to be poor estimators of ciprofloxacin activity against LLQR strains.  
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Guillermo Martín-Gutiérrez; José Manuel Rodríguez-Martínez; Álvaro Pascual; 
Jerónimo Rodríguez-Beltrán; Jesús Blázquez. Plasmidic qnr Genes Confer Clinical 
Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. 
Antimicrobial Agents and Chemotherapy 2017, 24: 61(4): pii: e02615-16. 
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Publication III: Urinary tract conditions affect fosfomycin activity against 
Escherichia coli strains harboring chromosomal mutations involved in fosfomycin 
uptake. 
Although fosfomycin is one of the most commonly used treatments for UTIs, the 
steps by which E. coli strains harbouring mutations related with fosfomycin-resistance 
arise and spread is not well understood. Fosfomycin resistance can be achieved by 
reducing permeability to fosfomycin through mutations in genes encoding the GlpT and 
UhpT transporters. Fosfomycin permeability can also be reduced by mutations in cyaA 
and/or ptsI genes, which regulate the intracellular cAMP levels necessary for 
fosfomycin-transporter activation. The presence of single chromosomal mutations and 
some of their combinations confer LLFR, but not clinical resistance, acting as a gateway 
for highly resistant subpopulations by the selection of additional LLFR mutations. 
However, there is a very low prevalence of fosfomycin-resistant E. coli strains 
from UTIs. This low prevalence may suggest that LLFR mutants will also present a 
very low prevalence. Fosfomycin-resistance is associated with a high biological cost, 
with decreased growth rates as well as decreased virulence. 
The objective of this work was to evaluate the impact of urinary tract 
physiological conditions on the antimicrobial activity of fosfomycin against a set of 
well-characterized isogenic strains harbouring deletions in the genes most frequently 
related with fosfomycin-resistance (ΔglpT, ΔuhpT, ΔcyaA, ΔptsI). Additionally we 
evaluated the impact of UTI conditions on bacterial fitness. A series of fosfomycin-
resistant E. coli clinical strains isolated from patients with UTI were also studied.  
The results presented here demonstrate that urinary tract conditions might have a 
profound impact on fosfomycin activity. The presence of low-pH values in urine and 
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anaerobic conditions increased fosfomycin activity, allowing the eradication of strains 
harbouring fosfomycin-resistance mutations. Furthermore, the presence of single and 
double-deletions were related with a significative decrease in maximal growth rates 
under urinary conditions. This work adds a new explanation to the low prevalence of E. 
coli fosfomycin-resistant variants in UTIs.  
 
Guillermo Martín-Gutiérrez, Fernando Docobo-Pérez, Jerónimo Rodriguez-Beltrán, 
José Manuel Rodríguez-Martínez, Javier Aznar, Álvaro Pascual, Jesús Blázquez. 
Urinary tract conditions affect fosfomycin activity against Escherichia coli strains 
harboring chromosomal mutations involved in fosfomycin uptake. Antimicrobial 
Agents and Chemotherapy 2017, 21: 62(1): pii: e01899-17 
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Multiple resistance to antibiotics represents a global health challenge that results 
in increased morbidity and mortality rates all over the world 
32
. For instance, the 
increasing prevalence of antibiotic-resistant uropathogens is likely to limit the 
effectiveness of our current therapeutic choices. Thus, UTIs are becoming increasingly 
difficult to treat owing to the widespread emergence of antibiotic resistance mechanisms 
226
. Furthermore, the high rates of recurrence in UTIs caused by susceptible 
uropathogens suggest that some antibiotics are not as effective as we thought. In this 
context, the current emergence of antibiotic-resistant strains, in conjunction with the 
high frequency of recurrent UTIs, emphasize the need for a better understanding of 
UTIs, as well as the effectiveness of antibiotics under physiological UTI conditions. On 
this basis, the main objective of the present thesis has been to evaluate the effect of 
urinary tract physiological conditions on two of the most used antibiotics for the 
treatment of UTIs caused by E. coli: ciprofloxacin and fosfomycin.  
The research presented in this thesis set out to identify the critical factors 
existing in the urinary tract that might promote or facilitate the survival of LLR mutants 
during therapeutic treatments. The main relevance of LLR strains is that they are 
considered an intermediary stage towards the development of high-resistance, carrying 
mutations or resistance genes that may result in a decrease in the effectiveness of the 
antibiotic 
39
. Unfortunately, there is not a standard definition for LLR in international 
clinical guidelines. MIC is defined as the minimal concentration of drug that prevents 
visible bacterial growth under strictly defined in vitro conditions, being measured using 
increasing concentration steps, with either broth dilution or gradient MIC assays 
227
. 
Thus, development of resistance can be considered the consequence of any genetic 
changes that increase the MIC of a strain to a level higher than the wild-type 
MIC/ecological cut-off. In contrast, clinical resistance is well defined and refers to the 
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consequences of genetic changes that increase the MIC of a strain to a level high 
enough to prevent successful treatment with standard drug therapy 
228
. In this way, LLR 
mutants are traditionally categorized as susceptible strains (MIC lower than the clinical 
breakpoint, and standard therapy likely to be successful), and hence are is difficult to 
detect by most standard susceptibility testing in Clinical Microbiology Laboratories 
39
. 
Furthermore, LLR strains appear to be a gate for the acquisition of high-level clinical 
resistance, which may have important consequences for the treatment and control of 
UTIs caused by these microorganisms. 
MIC determination gives a measure of growth inhibition under specific in vitro 
conditions, and its clinical usefulness requires that these MIC values would be able, in 
some way, to be translated into a prediction of the clinical outcome 
229
. Mueller-Hinton 
(MH) broth is the medium of choice for susceptibility testing of commonly isolated 
aerobic or facultative organisms 
230
. This medium shows acceptable batch-to-batch 
reproducibility and low concentration of inhibitors, with a stable pH value from 7.2 to 
7.4, supporting satisfactory growth of most common pathogens 
231
. Nonetheless, the 
situation in which antibiotics act under physiological conditions is quite different.  
Under physiological conditions, antibiotics interact with a set of proteins, 
cations, changing pH values and variable oxygen concentrations. As was mentioned in 
the Introduction (Chapter III), these conditions may compromise the activity of many 
antimicrobials, allowing the survival of a significant number of microorganisms. 
Despite this fact, little attention has been paid to the role of the physiological conditions 
during treatment. In the urinary tract, antibiotics face the presence of urine compounds, 
changing pH values and an oxygen-reduced concentration. To date, most of studies have 
focused on evaluating the effect of pH and urine on quinolone effectiveness. For 
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instance, Zeiler HJ 
232
 studied the influence of pH and human urine in quinolone 
susceptibility testing, showing that acidic pH was related to lower quinolone activity. 
Zhanel and colleagues 
233
 have also showed the reduction of ciprofloxacin activity under 
low-pH values in urine. Recently, other studies have presented similar results 
142
. 
However, there are few studies evaluating the effect of physiological urinary conditions 
in other antibiotics like fosfomycin. Furthermore, the effect of anaerobic conditions in 
combination with urine and low-pH has been overlooked in these studies.  
Of special interest is the impact of the urinary tract conditions and the presence 
LLR mutants during UTI treatment. The presence of LLR strains in the bladder could 
increase the possibility of the emergence of a clinically resistant phenotype to relevant 
antibiotics. Regrettably, few studies have shown the therapeutic impact of LLR in UTIs, 
either experimentally or in clinical reports. 
In Publications I and II we sought to evaluate the impact of the urinary tract 
physiological conditions (namely, growth in urine, pH, and anaerobiosis) on the 
antimicrobial activity of ciprofloxacin against a set of well-characterized isogenic 
LLQR strains carrying the most frequent chromosomal mutations and PMQR 
determinants. We have demonstrated that urinary tract physiological conditions could 
be an optimum scenario for the selection of strains harboring CMQR and PMQR genes, 
decreasing their susceptibility to ciprofloxacin and allowing the survival of E. coli 
strains that have traditionally been considered susceptible. This effect was also observed 
in LLQR mutants isolated from patients with UTI. It has been previously thought that 
multiple mutations are required to generate clinical ciprofloxacin resistance in E. coli 
strains. Nevertheless, our work shows how urinary tract conditions may provide an ideal 
scenario for the generation and selection of LLQR with single mutations or qnr genes, 
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which would allow its survival during ciprofloxacin treatmen under physiological 
concentrations, even though LLR strains were considered susceptible to 
fluoroquinolones. Furthermore, it has been demonstrated that a strong positive 
correlation between increased mutation rate and successful accumulation of quinolone 
resistance–associated mutations 98 exists in E. coli strains isolated from patients with 
UTI. In this manner, the presence of chromosomal mutations like GyrA S83L or 
plasmidic Qnr determinants increase the mutant prevention concentration, facilitating 
the selection of additional resistance mutations 
234
. 
  It should also be emphasized that fluoroquinolone antibiotics stimulate two 
important bacterial pathways to produce genetic variation: mutagenesis and 
recombination 
149,235.
 Ciprofloxacin produces double-strand breaks, potentially lethal 
DNA lesions that occur under physiological conditions through collapse of stalled 
replication forks, overlapping repair tracts or spontaneous breakage of DNA 
 236
. E. coli 
efficiently repairs double-strand breaks through a series of reactions carried out by 
enzymes participating in homologous recombination and replication that are induced by 
the SOS system. Thereby, ciprofloxacin acts as an inducer of the SOS system, which 
leads to an increase in mutagenesis, recombination and/or horizontal gene transfer, key 
processes for the emergence and spread of resistance 
237
. Therefore, fluoroquinolones 
can be viewed as a double-edged sword that may promote the generation of antibiotic 
resistance.  
It is also important to notice that E. coli strains growing in the urinary tract are 
frequently under stress because they are starved, under antibiotic treatment, or 
challenged by the need to colonize novel environments with low pH values or under the 
inhibitory effects of host defense mechanisms 
238
. Justice and colleagues demonstrated 
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that the ability to form filaments in bladder cells, an important virulence property that 
facilitates persistence in the murine cystitis model 
239
, is the result of bacterial SOS 
response induction. This result demonstrates that the SOS system is activated during 
bladder cell invasion. Thus, mutation and recombiation rates are probably much higher 
in the course of a UTI process than those determined in vitro. Furthermore, the urinary 
tract represents a heterogeneous environment, where bacteria are frequently attached to 
cell surfaces or inside the host cells. The presence of different microenvironments 
allows the emergence and co-existance of different phenotypes, which may promote 
higher degrees of antibiotic-resistant mutations.  
  Taken together, the arguments presented above let us to propose that prevalent 
mutations conferring LLQR phenotypes could provide the basal level of resistance 
needed to withstand the first hours during ciprofloxacin treatment under UTI conditions. 
Then, the surviving population will benefits from increased mutation and recombination 
rates, providing a window for the emergence of additional resistance. Therefore, 
ciprofloxacin might trigger a phenomenon known as “directional selection”         
(Figure 10), in which the susceptible phenotypes would be at a disadvantage compared 
to the more resistant phenotypes 
240
. This will cause a shift in the population towards 
more resistant strains, increasing their proportion. In our case, this effect is enhanced by 
the presence of LLQR strains and urinary physiological conditions, which reduce 
ciprofloxacin activity. This effect could explain, at least in part, the high rates of 
fluoroquinolones resistance in E. coli isolates from patients with UTI. In this way, it has 
been reported that patients previously treated with fluoroquinolones are more prone to 
urinary tract infection caused by ciprofloxacin-resistant E. coli strains 
241
. The study 
performed by Ena and colleagues 
241
 showed that previous treatment with quinolones, 
urinary abnormalities, patient age higher than 64 years and the presence of a urinary 
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catheter were independent factors related to infecions caused by quinolone-resistant 
microorganisms. Similar results have been reported in more recent studies 
86,88,242
. 
 
Figure 10. Directional selection as a product of antibiotic treatment under urinary tract 
physiological conditions. A) Initial population of susceptible E. coli strains in the urinary tract, 
with the presence of LLR mutants. B & C) If antibiotic activity is reduced under UTI 
conditions, LLR strains could be selected. In this sense, the antibiotic contributes to a 
directional selection, shifting the original susceptible population. Moreover the mutagenesis 
effect of antibiotics might contribute to the development of high-resistant strains. 
Andersson and Hughes 
33
 suggested that most resistance mechanisms incur a 
fitness cost for the bacterium, which is manifested by a decreased bacterial growth rate. 
Antibiotics target important functions such as cell wall synthesis or regulation of 
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chromosome supercoiling, hence mutations in genes participating in these processes 
arguably cause a reduction in fitness 
243
. To evaluate the impact of CMQR mutations on 
bacterial fitness, we studied the growth rates of these strains. Previously, Machuca and 
colleagues 
244
 showed that no significant differences, in terms of maximal growth rate, 
were observed during the exponential phase in a set of isogenic strains carrying the 
most frequent chromosomal mutations related with quinolones resistance. This 
experiment was performed in Lysogeny Broth (LB) and M9 media. Additionally, fitness 
cost was also measured with competition experiments using a murine model of systemic 
infection. Commonly, fitness experiments are performed in rich or in defined minimal 
media, which differs with real physiological conditions 
245.
 Fitness is relative and should 
be measured in physiological environments in order to establish its predictive value in 
determining the clinical outcome of infection 
243
. Therefore, a correct estimation of the 
potential fitness cost of antimicrobial resistance is an essential factor for predicting  the 
risk of resistance development in the urinary tract 
90
. For this reason, we performed 
growth curves in MH broth and urine at pH values of 7, 6 and 5, using an automated 
spectrophotometer under controlled conditions of temperature and shaking. The patterns 
of the curves obtained (Annexe II) were similar for all isogenic derivates within the 
same medium, showing that the LLQR mutations studied have a reduced effect in 
fitness, being the strains able to grow in urine at different pH values. Acidification of 
urine, including pH 5, led to only small decreases in growth, demonstrating that E. coli 
is well adapted to extreme pH values.  
The third part of this thesis aimed to investigate the effect of urinary tract 
physiological conditions on fosfomycin activity. The steps by which E. coli strains 
harboring mutations related with fosfomycin resistance arise and spread during UTI is 
not well known. For this reason, in Publication III we evaluated the effect of urine, pH 
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variation and anaerobiosis on fosfomycin MIC values against a set of isogenic strains 
carrying the most prevalent chromosomal mutations conferring fosfomycin-resistance 
and their combinations.  
The first concern that we found during this work was the lack of information 
about the prevalence of LLFR mutations in E. coli isolates from UTI, as well as the 
identification of the molecular mechanisms related with fosfomycin-resistance patterns. 
Nilsson and colleagues 
183
 performed the first study where fosfomycin-resisatance 
chromosomal mutations related were studied, analysing thirteen E. coli fosfomycin-
resistant strains from UTIs. In four isolates, gene-inactivating mutations were found in 
the uhpT and/or uhpA gene; and one strain carried a mutation in glpT as well as a 
deletion in uhpA. However, in eight strains the mechanisms of fosfomycin resistance 
were not identified. Similar results were obtained by Takahata and colleagues 
246
, where 
the lack of an entire uhpT gene and the insertion of an ISEcp1 element in the glpT gene 
were the most prevalent mutations in six E. coli fosfomycin-resistant clinical strains. In 
two further publications, the presence of fosfomycin-resistance mutations were studied 
in ESBL-producing E. coli strains, showing a wide range of mutations in uhpT, glpT, 
uhpA, and murA genes, as well as the presence of FosA 
193,216,247
. There are only two 
publications where LLFR strains have been studied, showing several mutations and 
deletions in uhpT, glpT, cyaA and ptsI genes 
183,192
. 
Although mutations in uhpT, glpT, cyaA and ptsI genes seem to be the main 
sources of fosfomycin resistance, there is no identified mutation-pattern of fosfomycin 
resistance. Unlike ciprofloxacin, the mutations and deletions found in fosfomycin-
resistant strains from previous works are largely different. Due to the lack of 
correlation, the impact of each mutation or partial deletion should be carefully studied.  
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In Publication III, we included the strain E. coli BW25113 and ten isogenic 
strains carrying the most prevalent single (ΔuhpT, ΔglpT, ΔcyaA and ΔptsI) and double 
deletions (ΔglpT-ΔuhpT, ΔglpT-ΔcyaA, ΔglpT-ΔptsI, ΔuhpT-ΔcyaA, ΔuhpT-ΔptsI and 
ΔptsI-ΔcyaA) in fosfomycin-resistance genes 217. In order to exclude the possibility that 
the effects observed were specific to the strain BW25113, we evaluate the effect of 
urinary tract physiological conditions in five E. coli clinical isolates from patients with 
UTI. Overall, our results demonstrate that urinary tract physiological conditions might 
have a profound impact on fosfomycin activity against strains with fosfomycin-
resistance mutations. Specifically, acid pH values and anaerobiosis have a great effect 
on fosfomycin activity, converting most of the strains categorized as resistant, according 
to the international guidelines, into susceptible. Nonetheless, the presence of urine 
increases the MIC values for some strains, although this effect is attenuated under acidic 
conditions and incubation under anaerobic conditions. We showed the effect of single 
and double-deletions on genes related with fosfomycin-resistance under physiological 
conditions, confirming that standard susceptibility testing could underestimate the effect 
of fosfomycin, mainly in patients with acid pH values in urine.  
Fosfomycin resistance has been previously related with a high biological cost, 
entailing a generally reduced fitness that compromises competition with the normal 
microbiota in the human host 
182
. The effect of fosfomycin-resistance mutations on 
fitness is of particular interest in UPECs, because if the cost is high enough, the resistant 
bacteria will not growth on the minimal rate needed to stablish an infection in the 
bladder 
183,248
. As was previously mentioned, to obtain a correct estimation of the 
potential fitness cost, we determined the maximal growth rates per hour in urine at 
different pH values for all isogenic strains, comparing the results obtained with those in 
MH. As can be observed in Publication III, all strains with single and double deletions 
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showed statistically significant decreases in growth rates when grew in urine at different 
pH values, compared with the strain BW25113. This result is in agreement with 
previous studies which demonstrated that fosfomycin-resistant strains show lower 
growth rates 
183
, decreased adhesion to uroepithelial cells as well as urinary catheters 
182
, and alteration in cell surface hydrophobicity 
249
. The possible causes of these defects 
in bacterial physiology are likely attributed to the pleiotropic effects caused by 
fosfomycin resistance mutations. For instance, mutations in cyaA and ptsI genes lead to 
lowered cAMP levels, which imply lower expression of uhpT and glpT, and thus, 
increased fosfomycin resistance. However, cAMP is a key metabolite in bacterial 
physiology and the perturbation of its level is expected to drastically alter bacterial 
homoestasis 
250
. In this line, it has been stated that a reduction of cAMP levels cause a 
reduction in pilus biosynthesis, reducing the virulence factors in fosfomycin-resistant 
strains 
183
. It should be noted that fitness cost of fosfomycin resistance needs to be 
measured for each particular species, being the observations made in just one species 
not extrapolable to another 
251
. The uptake of fosfomycin in Pseudomonas aeruginosa 
depends exclusively on GlpT transporter, which does not seem to be regulated by 
cAMP levels. Thus, fosfomycin resistance in P. aeruginosa was related with an absence 
of in vivo fitness cost 
251
. 
In the other hand, only increased MurA levels have been correlated with higher 
levels of fosfomycin resistance at a low fitness cost in E. coli 
200
. However, to date no 
clinical studies reporting strains with high MurA levels have been published. Moreover, 
as mentioned in Chapter III, there are few reports of clinical isolates showing 
mutations in the murA gene, and none in the catalytic site of MurA, because most of 
them reduce drastically bacterial cell viability. 
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In contrast with ciprofloxacin, treatment with fosfomycin does not activate the 
SOS system in E. coli 
200
. Thus, it has been demonstrated that fosfomycin treatment 
does not increase the number of fosfomycin-resistant mutants 
252
 nor the homologous 
recombination rates 
253
. Furthermore, the low prevalence of fosfomycin-resistant E. coli 
strains from patients with UTI may suggest that the prevalence of LLFR strains should 
be very low. If we combine the previous considerations with the high-fitness cost of 
these mutations and the increment of fosfomycin activity under UTI conditions, it leads 
to exactly the opposite situation of what was described in Figure 10. In this way, our 
results demonstrate that urinary tract physiological conditions might have a profound 
impact on fosfomycin activity against strains with fosfomycin-resistance mutations, 
adding a new explanation to the low prevalence of E. coli fosfomycin-resistant variants 
in UTIs. 
Concerning the clinical and physiological characteristics of patients with UTI 
caused by E. coli, there are several factors associated with urine pH modification that 
should be taken into consideration when the treatment is chosen. Pregnant women have 
an increased glomerular filtration rate and higher urinary calcium excretion throughout 
pregnancy, with higher urine pH values in the second and third trimesters 
254
. Thiazide 
diuretic intake is also associated with a higher urine pH by reducing the urinary uric 
acid excretion 
255
. Furthermore, there are genetic disorders that are related with urine 
alkalization. Thus, Gitelman syndrome is an autosomal recessive disorder of the 
thiazide-sensitive sodium chloride cotransporter, expressed at the distal convoluted 
tubule, which is accompanied by an inappropriately high urine pH 
256
. In these cases, if 
fosfomycin is the treatment of choice, the presence of LLFR could lead to treatment 
failure and the development of fosfomycin resistance. Thus, urinary pH values could 
have practical interest in the management of these patients, where the physician should 
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select the course best suited to the individual patient. 
  On the other side, there are also clinical factors related with urine acidification. 
It has been reported that the composition of the diet affects acid-base balance in the 
body. A higher protein intake significantly increases the renal acid excretion by 
increasing ammonium output, thus acidifying the urine 
257, 258
. Moreover, the effect of 
urine pH on ciprofloxacin and fosfomycin activity may become relevant in patients with 
certain underlying characteristics or diseases. It is known that patients with 
hypertension are associated with a lower urinary citrate and higher acid excretion, 
resulting in lower urine pH values 
259
. This effect can also be found in patients with type 
2 diabetes or metabolic acidosis 
260
. There are some patient characteristics that are 
related with lower pH values in urine, like older age or higher body weight 
261,262
. Some 
medications can also acidify urine, such as loop diuretics or mineralocorticoids 
263,264
. 
Consequently, if ciprofloxacin is the treatment chosen in patients with factors related to 
urine acidification, and the UTI is produced by LLQR mutants, it could result in 
therapeutic failure and increased selective pressure, promoting the development of 
bacterial resistance.  
Another posibility is modifying the urine pH of patients with UTI, either 
increasing urine pH by alkalinisation (e.g. by the use of potassium citrate or sodium 
bicarbonate 
265,266
) with the aim of increasing the activity of ciprofloxacin, or by 
acidifying the urine, with the aim of increasing the activity of fosfomycin. However, 
urinary pH modification is frequently difficult to achieve and is rarely, if ever, 
necessary. To acidify the urine, it is often necessary to modify the diet by restriction of 
agents that tend to alkalinize the urine (milk, fruit, juices, sodium bicarbonate) 
1
. 
Another major problem with acidification is that patients with renal insufficiency are 
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unable to excrete an acid load, and may become systematically acidotic when urinary 
acidification is attempted 
267
. Similar problems could be found with urine   
alkalinization 
268
. For this reason, the best choice should be the selection of the 
antibiotic therapy according to the clinical characteristics of the patient. 
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Conclusions 
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The studies developed in this Thesis have led to results that allow the following main 
conclusions:  
1. Urinary tract physiological conditions have a profound impact on ciprofloxacin 
and fosfomycin activity against E. coli strains harboring the most prevalent LLR 
mutations.  
 
2. The presence of urine, low-pH and anaerobiosis reduce ciprofloxacin activity. 
These conditions generate an ideal environment for the selection of strains 
harboring LLQR determinants, decreasing their susceptibility to ciprofloxacin, 
allowing for the survival of microorganisms traditionally considered as 
susceptible. 
 
3. Despite the general belief that multiple mutations are required to generate 
clinically important resistance in E. coli, the results presented here show that 
LLQR mutants are capable for surviving under physiological concentrations of 
ciprofloxacin in the bladder. 
 
4. The presence of acid pH values and anaerobiosis have a great effect on 
fosfomycin activity, converting most of the strains categorized as resistant, 
according to the international guidelines, into susceptible.  
 
 
5. The effects of urine, pH and anaerobiosis observed in the isogenic strains have 
been corroborated in clinical strains with LLR and high-resistance mutations.  
Conclusions 
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6. Internationally recommended methods for MIC determination produce poor 
estimations of ciprofloxacin and fosfomycin activity against LLR E. coli strains 
under urinary physiological conditions. Under this assumption, international 
guidelines should prompt a reconsideration of clinical breakpoints, taking into 
account physiological conditions during infection. 
 
7. Urinary pH values could have practical interest in the management of patients 
with UTI, where the physician should select the course best appropriate to the 
individual patient.  
 
 
 
 
 
 
 
 
 
 75 
 
 
 
 
Chapter VIII 
Bibliography  
  
76 
 
  
 77 
 
Bibliography:  
1. Mandell, Douglas, and Bennett’s. Principles and Practice of Infectious Diseases. 8th 
ed. Philadelphia: Elsevier Saunders; 2015. 
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs. Am J Med 2002; 113: 5–13. 
3. Bacheller CD, Bernstein JM. Urinary tract infections. Med Clin North Am 1997;     
81: 719–30. 
4. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;             
7: 653–60. 
5. Mulvey, Klumpp and Stapleton. Urinary tract infections: molecular pathogenesis and 
clinical management, 2th ed. Washington (DC): ASM Pres; 2017. 
6. Kanellopoulos TA, Salakos C, Spiliopoulou I, Ellina A, Nikolakopoulou NM, 
Papanastasiou DA. First urinary tract infection in neonates, infants and young children: 
a comparative study. Pediatr Nephrol 2006; 21:1131-7. 
7. Koeijers JJ, Verbon A, Kessels AGH, Bartelds A, Donkers G, Stobberingh EE. 
Urinary tract infection in male general practice patients: uropathogens and antibiotic 
susceptibility. Urology 2010; 76: 336–40. 
8. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat 
Rev Nephrol 2008; 4: 252–64.  
9. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: 
epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 
13: 269–84. 
  
78 
10. Spurbeck RR, Mobley HLT. Chapter 9 - Uropathogenic Escherichia coli. In: 
Donnenberg MS, ed. Escherichia coli (Second Edition). Boston: Academic Press, 2013; 
275–304. 
11. Mobley HLT, Donnenberg MS, Hagan EC. Uropathogenic Escherichia coli. EcoSal 
Plus 2009; 3. 
12. Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet MJ, Schembri MA. 
Uropathogenic Escherichia coli virulence and innate immune responses during urinary 
tract infection. Curr Opin Microbiol 2013; 16: 100–7. 
13. Lewis AJ, Richards AC, Mulvey MA. Invasion of host cells and tissues by 
uropathogenic bacteria. Microbiol Spectr 2016; 4. 
14. Eto DS, Sundsbak JL, Mulvey MA. Actin-gated intracellular growth and resurgence 
of uropathogenic Escherichia coli. Cell Microbiol 2006; 8: 704–17. 
15. Justice SS, Hunstad DA, Cegelski L, Hultgren SJ. Morphological plasticity as a 
bacterial survival strategy. Nat Rev Microbiol 2008; 6: 162–8. 
16. Barber AE, Norton JP, Wiles TJ, Mulvey MA. Strengths and limitations of model 
systems for the study of urinary tract infections and related pathologies. Microbiol Mol 
Biol Rev 2016; 80: 351–67.  
17. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future 
prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6: 17–27. 
18. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of 
uncomplicated lower urinary tract infection in women illustrated by a randomized 
placebo controlled study. Scand J Infect Dis 2004; 36: 296–301. 
 79 
 
19. Ejrnaes K, Sandvang D, Lundgren B, Ferry S, Holm S, Monsen T, Lundholm R, 
Frimodt-Møller N. Pulsed-field gel electrophoresis typing of Escherichia coli strains 
from samples collected before and after pivmecillinam or placebo treatment of 
uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol 
2006; 44: 1776–81. 
20. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus 
placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of 
randomized controlled trials. J Infect 2009; 58: 91–102. 
21. Schwartz DJ, Conover MS, Hannan TJ, Hultgren SJ. Uropathogenic Escherichia 
coli superinfection enhances the severity of mouse bladder infection. PLOS Pathog 
2015; 11: e1004599. 
22. Marschall J, Zhang L, Foxman B, Warren DK, Henderson JP, CDC Prevention 
Epicenters Program. Both host and pathogen factors predispose to Escherichia coli 
urinary-source bacteremia in hospitalized patients. Clin Infect Dis 2012; 54: 1692–8. 
23. Grabe M, Bjerklund-Johansen TE, Cai T, Çek M, Köves B, Naber KG, Pickard RS, 
Tenke P, Wagenlehner F, Wullt B. Guidelines on urological infection 2015.  
24. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle 
LE, Raz R, Schaeffer AJ, Soper DE, Infectious Disease Society of America, European 
Society for Microbiology and Infectious Diseases. International clinical practice 
guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in 
women: A 2010 update by the Infectious Diseases Society of America and the European 
Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-120. 
 
  
80 
25. Paterson DL. ‘Collateral damage’ from cephalosporin or quinolone antibiotic 
therapy. Clin Infect Dis 2004; 38: S341–5.  
26. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis 
Rep 2008; 10: 499–504.  
27. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the 
treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010;     
65: iii25-iii33.  
28. Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, Nicolle LE. A 
prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute 
urinary tract infection in patients with spinal cord injury. Clin Infect Dis 2004;            
39: 658–64. 
29. Nicolle LE. A practical guide to antimicrobial management of complicated urinary 
tract infection. Drugs Aging 2001; 18: 243–54. 
30. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of 
antimicrobial consumption in human communities and the frequency of resistance.   
Proc Natl Acad Sci 1999; 96: 1152–6.  
31. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and 
responses. Nat Med 2004; 10: S122–9.  
32. Nolan LK, Li G, Logue CM. Origin and dissemination of antimicrobial resistance 
among uropathogenic Escherichia coli. Microbiol Spectr 2015; 3. 
33. Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. 
Nat Rev Microbiol 2014; 12: 465–78. 
 81 
 
34. Lawrenson RA, Logie JW. Antibiotic failure in the treatment of urinary tract 
infections in young women. J Antimicrob Chemother 2001; 48: 895–901.  
35. Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. Chromosomal 
restriction fragment length polymorphism analysis of Escherichia coli strains causing 
recurrent urinary tract infections in young women. J Infect Dis 1995; 172: 440–5. 
36. Ikäheimo R, Siitonen A, Heiskanen T, Kärkkäinen U, Kuosmanen P, Lipponen P, 
Mäkelä PH. Recurrence of urinary tract infection in a primary care setting: analysis of a 
1-year follow-up of 179 women. Clin Infect Dis 1996; 22: 91–9. 
37. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of 
intracellular bacterial communities in human urinary tract infection. PLOS Med 2007; 4: 
e329. 
38. Hughes D. Selection and evolution of resistance to antimicrobial drugs. IUBMB Life 
2014; 66: 521–9. 
39. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug 
Resist Updat 2001; 4: 93–105. 
40. Marin SJ, Coles R, Merrell M, McMillin GA. Quantitation of benzodiazepines in 
urine, serum, plasma, and meconium by LC-MS-MS. J Anal Toxicol 2008; 32: 491–8. 
41. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, NakamuraK, Niki Y, Nakano S. 
Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and 
antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob Agents 
Chemother 1999; 43: 525–9.  
  
82 
42. Cahill DJ, Fry CH, Foxall PJD. Variation in urine composition in the human urinary 
tract: evidence of urothelial function in situ? J Urol 2003; 169: 871–4.  
43. Özdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A. Assessment of in vivo 
CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin 
Pharmacol 2004; 44: 1398–404.  
44. So W, Crandon JL, Nicolau DP. Effects of urine matrix and pH on the potency of 
delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella 
pneumoniae. J Urol 2015; 194: 563–70. 
45. Zaharchuk G, Busse RF, Rosenthal G, Manley GT, Glenn OA, Dillon WP. 
Noninvasive oxygen partial pressure measurement of human body fluids in vivo using 
magnetic resonance imaging. Acad Radiol 2006; 13: 1016–24. 
46. Giannakopoulos X, Evangelou A, Kalfakakou V, Grammeniatis E, Papandropoulos 
I, Charalambopoulos K. Human bladder urine oxygen content: implications for urinary 
tract diseases. Int Urol Nephrol 1997; 29: 393–401. 
47. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N, Chan 
CT, Lobritz MA, Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M, Ralifo PS, 
Allison KR, Khalil AS, Ting AY, Walker GC, Collins JJ. Antibiotics induce redox-
related physiological alterations as part of their lethality. Proc Natl Acad Sci 2014;    
111: E2100–9.  
48. Zhao X, Drlica K. Reactive oxygen species and the bacterial response to lethal 
stress. Curr Opin Microbiol 2014; 21: 1–6.  
 83 
 
49. Liu Y, Imlay JA. Cell death from antibiotics without the involvement of reactive 
oxygen species. Science 2013; 339: 1210–3. 
50. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. Killing by bactericidal 
antibiotics does not depend on reactive oxygen species. Science 2013; 339: 1213–6. 
51. Van Acker H, Coenye T. The role of reactive oxygen species in antibiotic-mediated 
killing of bacteria. Trends Microbiol 2017. 
52. Andersson DI, Hughes D. Evolution of antibiotic resistance at non-lethal drug 
concentrations. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 
2012; 15: 162–72. 
53. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: How concerned 
should we be? CMAJ Can Med Assoc J 2009; 180: 408–15.  
54. Gerhardt C. Untersuchungen über die organischen Basen. Justus Liebigs Ann Chem 
1842; 42: 310–3. 
55. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-Naphthyridine 
derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962;         
91: 1063–5. 
56. Emmerson AM, Jones AM. The quinolones: decades of development and use. J 
Antimicrob Chemother 2003; 51 Suppl 1: 13–20. 
57. Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M. Quinolones: 
from antibiotics to autoinducers. FEMS Microbiol Rev 2011; 35: 247–74. 
  
84 
58. Etienne M, Lefebvre E, Frebourg N, Hamel H, Pesterl-Caron M, Caron F, Bacyst 
Study Group. Antibiotic treatment of acute uncomplicated cystitis based on rapid urine 
test and local epidemiology: lessons from a primary care series. BMC Infect Dis      
2014; 14: 137.  
59. Starre WE van der, Nieuwkoop C van, Paltansing S, van't Wout JW, Groeneveld 
GH, Becker MJ, Koster T, Watter-Louis GH, Delfos NM, Ablig HC, Leyten EM, Blom 
JW, van Dissel JT. Risk factors for fluoroquinolone-resistant Escherichia coli in adults 
with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011; 66: 
650–6.  
60. van den Broek d’Obrenan J, Verheij TJM, Numans ME, van der Velden AW. 
Antibiotic use in Dutch primary care: relation between diagnosis, consultation and 
treatment. J Antimicrob Chemother 2014; 69: 1701–7. 
61. Parasuraman R, Julian K, AST Infectious Diseases Community of Practice. Urinary 
tract infections in solid organ transplantation. Am J Transplant 2013; 13: 327–36. 
62. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute 
oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1986; 30: 444–6.  
63. Höffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of 
ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 
1985; 27: 375–9.  
64. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles 
of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 
1992; 36: 993–6.  
 85 
 
65. Staib AH, Beermann D, Harder S, Fuhr U, Liermann D. Absorption differences of 
ciprofloxacin along the human gastrointestinal tract determined using a remote-control 
drug delivery device (HF-capsule). Am J Med 1989; 87: 66S–69S. 
66. Harder S, Fuhr U, Beermann D, Staib AH. Ciprofloxacin absorption in different 
regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin 
Pharmacol 1990; 30: 35–9.  
67. Wagenlehner FME, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG. 
Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin 
(500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral 
dose. Int J Antimicrob Agents 2006; 28: 551–9. 
68. Arredondo-García JL, Figueroa-Damián R, Rosas A, Jáuregui A, Corral M, Costa 
A, Merlos RM, Ríos-Fabra A, Amábile-Cuevas CF, Hernández-Oliva GM, Olguín J, 
Cardeñosa-Guerra O, uUTI Latin American Study Group. Comparison of short-term 
treatment regimen of ciprofloxacin versus long-term treatment regimens of 
trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract 
infections: a randomized, multicentre, open-label, prospective study. J Antimicrob 
Chemother 2004; 54: 840–3. 
69. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial 
comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-
trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.   
J Antimicrob Chemother 1999; 43 Suppl A: 67–75. 
  
86 
70. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. 
Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in 
women: a randomized trial. JAMA 2005; 293: 949–55. 
71. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A Double-Blind, Randomized 
Comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 
mg twice-daily for 10 days for the treatment of complicated urinary tract infections and 
acute pyelonephritis. Urology 2008; 71: 17–22.  
72. Raz R, Naber KG, Raizenberg C, Rohana Y, Unamba-Oparah I, Korfman G,     
Yaniv I. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the 
treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect 
Dis 2000; 19: 327–31.  
73. Henry DC, Nenad RC, Iravani A, Tice AD, Mansfield DL, Magner DJ, Dorr MB, 
Talbot GH. Comparison of sparfloxacin and ciprofloxacin in the treatment of 
community-acquired acute uncomplicated urinary tract infection in women. Clin Ther 
1999; 21: 966–81.  
74. Cox CE, Marbury TC, Pittman WG, Brown GL, Auerbach SM, Fox BC, Yang JY. 
A randomized, double-blind, multicenter comparison of gatifloxacin versus 
ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. 
Clin Ther 2002; 24: 223–36.  
75. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol 
Mol Biol Rev 1997; 61: 377–92. 
76. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased 
accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51: 1109–17. 
 87 
 
77. Kampranis SC, Bates AD, Maxwell A. A model for the mechanism of strand 
passage by DNA gyrase. Proc Natl Acad Sci U S A 1999; 96: 8414–9.  
78. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone-mediated bacterial death. 
Antimicrob Agents Chemother 2008; 52: 385–92. 
79. Redgrave LS, Sutton SB, Webber MA, Piddock LJV. Fluoroquinolone resistance: 
mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 
2014; 22: 438–45. 
80. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone 
resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents 
Chemother 2005; 49: 118–25. 
81. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. 
Biochemistry (Mosc) 2014; 53: 1565–74. 
82. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to 
networks. Nat Rev Microbiol 2010; 8: 423–35. 
83. Van Bambeke F, Glupczynski, Y, Mingeot-Leclercq, MP, Tulkens PM.         
Chapter 130: Mechanisms of Action. In: Cohen J, Powderly WG, Opel SM, editors. 
Infectious Diseases, 3d edition; Philadelphia: Mosby Elsevier, 2010: 1304. 
84. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated 
urinary tract infections and fluoroquinolone resistance: a prospective observational 
study. Ann Clin Microbiol Antimicrob 2009; 8: 27. 
85. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global 
targets for antimicrobial resistance. Science 2016; 353: 874–5. 
  
88 
86. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired 
urinary tract infection due to quinolone-resistant E. coli. Infection 2008; 36: 41–5. 
87. Park K-H, Oh WS, Kim ES, Park SW, Hur JA, Kim YK, Moon C, Lee JH, Lee CS, 
Kim BN. Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia 
coli in women with acute pyelonephritis in the emergency department. Int J Infect Dis 
2014; 23: 8–13. 
88. Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study 
Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated 
from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 
2005; 56: 914–8. 
89. Nicoletti J, Kuster SP, Sulser T, Zbinden R, Ruef C, Ledergerber B, Weber R.. Risk 
factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a 
tertiary care urology department in Switzerland. Swiss Med Wkly 2010; 140: w13059. 
90. Dickstein Y, Geffen Y, Andreassen S, Leibovici L, Paul M. Predicting antibiotic 
resistance in urinary tract infection patients with prior urine cultures. Antimicrob Agents 
Chemother 2016; 60: 4717–21.  
91. Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic 
Resistance among urinary isolates from female outpatients in the United States in 2003 
and 2012. Antimicrob Agents Chemother 2016; 60: 2680–3. 
92. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in 
Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005; 
25: 358–73. 
 89 
 
93. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-
determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob 
Agents Chemother 1990; 34: 1271–2.  
94. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. Quinolone 
resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. 
Antimicrob Agents Chemother 1991; 35: 1647–50.  
95. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann 
N Y Acad Sci 2015; 1354: 12–31. 
96. Chaniotaki S, Giakouppi P, Tzouvelekis LS, Panagiotakos D, Kozanitou M, 
Petrikkos G, Avlami A, Vatopoulos AC, WHONET Study Group. Quinolone resistance 
among Escherichia coli strains from community-acquired urinary tract infections in 
Greece. Clin Microbiol Infect 2004; 10: 75–8. 
97. Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone 
resistance in urinary tract pathogens. J Antimicrob Chemother 2006; 58: 1274–8. 
98. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of 
fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract 
infections. Antimicrob Agents Chemother 2003; 47: 3222–32. 
99. Takahashi A, Muratani T, Yasuda M, Takahashi S, Moden K, Ishikawa K, Kiyota 
H, Arakawa S, Matsumoto T, Shima H, Kurazono H, Yamamoto S. Genetic profiles of 
fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: 
phylogeny, virulence factors, PAIusp subtypes, and mutation patterns. J Clin Microbiol 
2009; 47: 791–5. 
  
90 
100. Blair JMA, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathöfer U, 
Ruggerone P, Vargiu AV, Baylay Aj, Smith HE, Brandon Y, galloway D, Piddock LJ. 
AcrB drug-binding pocket substitution confers clinically relevant resistance and altered 
substrate specificity. Proc Natl Acad Sci 2015; 112: 3511–6.  
101. Yamamoto K, Tamai R, Yamazaki M, Inaba T, Sowa Y, Kawagishi I. Substrate-
dependent dynamics of the multidrug efflux transporter AcrB of Escherichia coli. Sci 
Rep 2016; 6: 21909.  
102. Opperman TJ, Kwasny SM, Kim H-S, Nguyen ST, Houseweart C, D'Souza S, 
Walker GC, Peet NP, Nikaido H, Bowlin TL. Characterization of a novel 
pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob 
Agents Chemother 2014; 58: 722–33. 
103. Blair JMA, Smith HE, Ricci V, Lawler AJ, Thompson LJ, Piddock LJV. 
Expression of homologous RND efflux pump genes is dependent upon AcrB 
expression: implications for efflux and virulence inhibitor design. J Antimicrob 
Chemother 2015; 70: 424–31.  
104. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly 
fluoroquinolone-resistant clinical Escherichia coli Strains from China: role of acrR 
mutations. Antimicrob Agents Chemother 2001; 45: 1515–21.  
105. Wiggins P. Efflux pumps: an answer to Gram-negative bacterial resistance? Expert 
Opin Investig Drugs 2004; 13: 899–902.  
106. Alekshun MN, Levy SB. The mar regulon: multiple resistance to antibiotics and 
other toxic chemicals. Trends Microbiol 1999; 7: 410–3. 
 91 
 
107. Kishii R, Takei M. Relationship between the expression of ompF and quinolone 
resistance in Escherichia coli. J Infect Chemother 2009; 15: 361–6. 
108. Baslé A, Rummel G, Storici P, Rosenbusch JP, Schirmer T. Crystal structure of 
osmoporin OmpC from E. coli at 2.0 A. J Mol Biol 2006; 362: 933–42. 
109. Fàbrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to 
quinolones. Microb Biotechnol 2009; 2: 40–61. 
110. Chen S, Zhang A, Blyn LB, Storz G. MicC, a second small-RNA regulator of Omp 
protein expression in Escherichia coli. J Bacteriol 2004; 186: 6689–97.  
111. Mizuno T, Chou MY, Inouye M. A unique mechanism regulating gene expression: 
translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad 
Sci U S A 1984; 81: 1966–70.  
112. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim 
Biophys Acta 2009; 1794: 808–16.  
113. Pagès J-M, James CE, Winterhalter M. The porin and the permeating antibiotic: a 
selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008;             
6: 893–903. 
114. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a 
transferable plasmid. The Lancet 1998; 351: 797–9. 
115. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone 
resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664–89. 
  
92 
116. Liu M, Wong MHY, Chen S. Mechanisms of fluoroquinolone resistance in Vibrio 
parahaemolyticus. Int J Antimicrob Agents 2013; 42: 187–8.  
117. Xia R, Guo X, Zhang Y, Xu H. qnrVC-like gene located in a novel complex class 
1 integron harboring the ISCR1 element in an Aeromonas punctata strain from an 
aquatic environment in Shandong Province, China. Antimicrob Agents Chemother 2010; 
54: 3471–4. 
118. Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque AS, Salam MA, 
Khan WA, Qadri F, Calderwood SB, Jacoby GA, Hooper DC. Transferable quinolone 
resistance in Vibrio cholerae. Antimicrob Agents Chemother 2010; 54: 799–803.  
119. Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. 
Microbiol Spectr 2014; 2.  
120. Jacoby GA, Cattoir V, Hooper D, Martínez-Martínez L, Nordmann P, Pascual A, 
Poirel L, Wang M. qnr Gene nomenclature. Antimicrob Agents Chemother 2008; 52: 
2297–9. 
121. Jacoby GA, Corcoran MA, Mills DM, Griffin CM, Hooper DC. Mutational 
analysis of quinolone resistance protein QnrB1. Antimicrob Agents Chemother 2013; 
57: 5733–6. 
122. Mérens A, Matrat S, Aubry A, Lascols C, Jarlier V, Soussy CJ, Cavallo JD, 
Cambau E. The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite 
effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone 
complex. J Bacteriol 2009; 191: 1587–94.  
 93 
 
123. Tavío MM, Jacoby GA, Hooper DC. QnrS1 structure-activity relationships.           
J Antimicrob Chemother 2014; 69: 2102–9. 
124. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents 
Chemother 2009; 53: 2227–38. 
125. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J 
Med 2006; 119: S20–8. 
126. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: 
a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;        
12: 83–8. 
127. de Toro M, Rojo-Bezares B, Vinué L, Undabeitia E, Torres C, Sáenz Y. In vivo 
selection of aac(6’)-Ib-cr and mutations in the gyrA gene in a clinical qnrS1-positive 
Salmonella enterica serovar Typhimurium DT104B strain recovered after 
fluoroquinolone treatment. J Antimicrob Chemother 2010; 65: 1945–9. 
128. Park Y-J, Yu JK, Kim SY, Lee S, Jeong SH. Prevalence and characteristics of qnr 
determinants and aac(6’)-Ib-cr among ciprofloxacin-susceptible isolates of Klebsiella 
pneumoniae in Korea. J Antimicrob Chemother 2010; 65: 2041–3. 
129. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, 
Konda T, Arakawa Y. New plasmid-mediated fluoroquinolone efflux pump, QepA, 
found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 2007; 51: 
3354–60. 
  
94 
130. Hansen LH, Johannesen E, Burmølle M, Sørensen AH, Sørensen SJ. Plasmid-
encoded multidrug efflux pump conferring resistance to olaquindox in Escherichia coli. 
Antimicrob Agents Chemother 2004; 48: 3332–7. 
131. Sørensen AH, Hansen LH, Johannesen E, Sørensen SJ. Conjugative plasmid 
conferring resistance to olaquindox. Antimicrob Agents Chemother 2003; 47: 798–9.  
132. Hansen LH, Jensen LB, Sørensen HI, Sørensen SJ. Substrate specificity of the 
OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria. J 
Antimicrob Chemother 2007; 60: 145–7. 
133. Longhi C, Conte MP, Marazzato M, Iebba V, Totino V, Santangelo F, Gallinelli C, 
Pallecchi L, Riccobono E, Schippa S, Comanducci A. Plasmid-mediated 
fluoroquinolone resistance determinants in Escherichia coli from community 
uncomplicated urinary tract infection in an area of high prevalence of quinolone 
resistance. Eur J Clin Microbiol Infect Dis 2011; 31: 1917–21. 
134. Sana F, Mabrouka S, Claudine Q, Faouzi SA, Ilhem BBB, Véronique D. 
Prevalence and characterization of uropathogenic Escherichia coli harboring plasmid-
mediated quinolone resistance in a Tunisian university hospital. Diagn Microbiol Infect 
Dis 2014; 79: 247–51. 
135. Pasom W, Chanawong A, Lulitanond A, Wilailuckana C, Kenprom S, Puang-
Ngern P. Plasmid-mediated quinolone resistance genes, aac(6’)-Ib-cr, qnrS, qnrB, and 
qnrA, in urinary isolates of Escherichia coli and Klebsiella pneumoniae at a teaching 
hospital, Thailand. Jpn J Infect Dis 2013; 66: 428–32. 
136. Briales A, Rodríguez-Martínez JM, Velasco C, de Alba PD, Rodríguez-Baño J, 
Martínez-Martínez J, Pascual A. Prevalence of plasmid-mediated quinolone resistance 
 95 
 
determinants qnr and aac(6’)-Ib-cr in Escherichia coli and Klebsiella pneumoniae 
producing extended-spectrum β-lactamases in Spain. Int J Antimicrob Agents 2012;    
39: 431–4. 
137. Völgyi G, Vizserálek G, Takács-Novák K, Avdeef A, Tam KY. Predicting the 
exposure and antibacterial activity of fluoroquinolones based on physicochemical 
properties. Eur J Pharm Sci 2012; 47: 21–7. 
138. Nurchi VM, Crisponi G, Lachowicz JI, Zoroddu MA, Peana M, Medici S, Veclani 
D, Tolazzi M, Melchior A. Fluoroquinolones: a micro-species equilibrium in the 
protonation of amphoteric compounds. Eur J Pharm Sci 2016; 93: 380–91. 
139. Piddock LJ. Mechanism of quinolone uptake into bacterial cells. J Antimicrob 
Chemother 1991; 27: 399–403. 
140. Danelon C, Nestorovich EM, Winterhalter M, Ceccarelli M, Bezrukov SM. 
Interaction of zwitterionic penicillins with the OmpF channel facilitates their 
translocation. Biophys J 2006; 90: 1617–27. 
141. Roca Jalil ME, Baschini M, Sapag K. Influence of pH and antibiotic solubility on 
the removal of ciprofloxacin from aqueous media using montmorillonite. Appl Clay Sci 
2015; 114: 69–76.  
142. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. Impact of pH on bacterial 
growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol 2011; 
162: 249–52. 
143. Marshall AJ, Piddock LJ. Interaction of divalent cations, quinolones and bacteria.  
J Antimicrob Chemother 1994; 34: 465–83. 
  
96 
144. Lecomte S, Baron MH, Chenon MT, Coupry C, Moreau NJ. Effect of magnesium 
complexation by fluoroquinolones on their antibacterial properties. Antimicrob Agents 
Chemother 1994; 38: 2810–6.  
145. Turel I. The interactions of metal ions with quinolone antibacterial agents. Coord 
Chem Rev 2002; 232: 27–47.  
146. Hartshorn EA, Lomaestro BM, Bailie GR. Quinolone-cation interactions: A 
review. DICP 1991; 25: 1249–58.  
147. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, 
ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or 
trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob 
Chemother 2004; 53: 252–7.  
148. Kottur J, Nair DT. Reactive oxygen species play an important role in the 
bactericidal activity of quinolone antibiotics. Angew Chem Int Ed Engl 2016;              
55: 2397–400. 
149. López E, Elez M, Matic I, Blázquez J. Antibiotic-mediated recombination: 
ciprofloxacin stimulates SOS-independent recombination of divergent sequences in 
Escherichia coli. Mol Microbiol 2007; 64: 83–93. 
150. Beaber JW, Hochhut B, Waldor MK. SOS response promotes horizontal 
dissemination of antibiotic resistance genes. Nature 2004; 427: 72–4. 
151. Ysern P, Clerch B, Castańo M, Gibert I, Barbé J, Llagostera M. Induction of SOS 
genes in Escherichia coli and mutagenesis in Salmonella typhimurium by 
fluoroquinolones. Mutagenesis 1990; 5: 63–6.  
 97 
 
152. Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to 
multidrug resistance via radical-induced mutagenesis. Mol Cell 2010; 37: 311–20. 
153. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. Molecular mechanisms and 
clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2013;          
2: 217–36. 
154. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin 
Microbiol Rev 2016; 29: 321–47. 
155. Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic 
produced by strains of streptomyces. Science 1969; 166: 122–3. 
156. Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect 
Med 2017; 7: a025262.  
157. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use 
beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;                    
46: 1069–77.  
158. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for 
the treatment of multidrug-resistant, including extended-spectrum β-lactamase 
producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 
10: 43–50.  
159. Barry AL, Brown SD. Antibacterial spectrum of fosfomycin trometamol. J 
Antimicrob Chemother 1995; 35: 228–30.  
160. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. 
Intravenous fosfomycin for the treatment of nosocomial infections caused by 
  
98 
carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective 
evaluation. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2010;     
16: 184–6. 
161. Vergara-López S, Domínguez MC, Conejo MC, Pascual Á, Rodríguez-Baño J. 
Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a 
case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 
metallo-β-lactamase-producing Klebsiella oxytoca. J Antimicrob Chemother 2015;      
70: 313–5. 
162. Simkins J, Fan J, Camargo JF, Aragon L, Frederick C. Intravenous fosfomycin 
treatment for carbapenem-resistant Klebsiella pneumoniae in the United States. Ann 
Pharmacother 2015; 49: 1177–8. 
163. Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, 
Gardiner BJ, Frauman AG. Fosfomycin for treatment of prostatitis: New Tricks for Old 
Dogs. Clin Infect Dis 2015; 61: 1141–3. 
164. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother 1994; 34: 853–8.  
165. Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin 
trometamol. Chemotherapy 1993; 39: 297–301. 
166. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its 
antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-
dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 
53: 637–56. 
 99 
 
167. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 
Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for 
the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-
acetylglucosamine and the drug fosfomycin. Structure 1996; 4: 1465–74.  
168. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of 
fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364–86. 
169. Huang Y, Lemieux MJ, Song J, Auer M, Wang D-N. Structure and mechanism of 
the glycerol-3-phosphate transporter from Escherichia coli. Science 2003; 301: 616–20. 
170. Hall JA, Maloney PC. Altered oxyanion selectivity in mutants of UhpT, the Pi-
linked sugar phosphate carrier of Escherichia coli. J Biol Chem 2005; 280: 3376–81. 
171. Fann MC, Maloney PC. Functional symmetry of UhpT, the sugar phosphate 
transporter of Escherichia coli. J Biol Chem 1998; 273: 33735–40. 
172. Schwöppe C, Winkler HH, Neuhaus HE. Connection of transport and sensing by 
UhpC, the sensor for external glucose-6-phosphate in Escherichia coli. Eur J Biochem 
2003; 270: 1450–7. 
173. Chekan JR, Cogan DP, Nair SK. Molecular basis for resistance against 
phosphonate antibiotics and herbicides. MedChemComm 2016; 7: 28–36. 
174. Schumacher G, Bussmann K. Cell-free synthesis of proteins related to sn-glycerol-
3-phosphate transport in Escherichia coli. J Bacteriol 1978; 135: 239–50.  
175. Merkel TJ, Dahl JL, Ebright RH, Kadner RJ. Transcription activation at the 
Escherichia coli uhpT promoter by the catabolite gene activator protein. J Bacteriol 
1995; 177: 1712–8. 
  
100 
176. Grainger DC, Hurd D, Harrison M, Holdstock J, Busby SJW. Studies of the 
distribution of Escherichia coli cAMP-receptor protein and RNA polymerase along the 
E. coli chromosome. Proc Natl Acad Sci U S A 2005; 102: 17693–8. 
177. Green J, Irvine AS, Meng W, Guest JR. FNR-DNA interactions at natural and 
semi-synthetic promoters. Mol Microbiol 1996; 19: 125–37. 
178. Kurabayashi K, Tanimoto K, Fueki S, Tomita H, Hirakawa H. Elevated expression 
of GlpT and UhpT via FNR activation contributes to increased fosfomycin 
susceptibility in Escherichia coli under anaerobic conditions. Antimicrob Agents 
Chemother 2015; 59: 6352–60.  
179. Eschenburg S, Priestman M, Schönbrunn E. Evidence that the fosfomycin target 
Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for 
product release. J Biol Chem 2005; 280: 3757–63. 
180. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur 
J Clin Microbiol Infect Dis 2010; 29: 127–42. 
181. Gobernado M, Valdés L, Alós JI, García-Rey C, Dal-Ré R, García-de-Lomas J, 
Spanish Surveillance Group for Urinary Pathogens. Antimicrobial susceptibility of 
clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year 
period in Spain. Rev Espanola Quimioter 2007; 20: 68–76. 
182. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of 
fosfomycin against gram-negative urinary pathogens and the biological cost of 
fosfomycin resistance. Int J Antimicrob Agents 2003; 22 Suppl 2: 53–9. 
 101 
 
183. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs 
and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents 
Chemother 2003; 47: 2850–8.  
184. Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic resistance of 
Escherichia coli from community-acquired urinary tract infections in relation to 
demographic and clinical data. Clin Microbiol Infect 2005; 11: 199–203. 
185. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, 
Martínez-Brocal A, Miranda-Casas C, Navarro-Marí JM, Gutiérrez-Fernández J.. 
Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: 
a 7-year surveillance study. Am J Infect Control 2014; 42: 1033–8. 
186. Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, Arakawa Y. Prevalence of 
acquired fosfomycin resistance among extended-spectrum β-lactamase-producing 
Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-
composite transposon surrounding fosA3. J Antimicrob Chemother 2012; 67: 2843–7. 
187. Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T. In vitro activity of 
fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary 
tract bacteria. J Coll Physicians Surg 2014; 24: 914–7. 
188. Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, 
Park K. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing 
Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract 
infection: focus on susceptibility to fosfomycin. Int Urol Nephrol 2015; 47: 1059–66. 
189. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez Gil 
González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita 
  
102 
A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract 
infections caused by extended-spectrum beta-lactamase (ESBL)-producing 
enterobacteria. Int J Clin Pract 2012; 66: 891–6. 
190. Asencio MÁ, Huertas M, Carranza R, Franco M, Castellanos J, Barberá JR, Conde 
MC, Tenías JM. Tendencia de sensibilidad de los patógenos bacterianos más 
frecuentemente aislados en el Hospital General La Mancha Centro durante el periodo 
2010-2012. Rev Espanola Quimioter 2014; 27: 261–8. 
191. de Cueto M, López L, Hernández JR, Morillo C, Pascual A. In vitro activity of 
fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and 
Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob 
Agents Chemother 2006; 50: 368–70. 
192. Ohkoshi Y, Sato T, Suzuki Y, Mechanism of reduced susceptibility to fosfomycin 
in Escherichia coli clinical isolates. BioMed Res Int 2017; 2017: 5470241. 
193. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo 
FJ, Campos J, Spanish ESBL-EARS-Net Study Group. Parallel increase in community 
use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase 
(ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459–63.  
194. Kadner RJ, Winkler HH. Isolation and characterization of mutations affecting the 
transport of hexose phosphates in Escherichia coli. J Bacteriol 1973; 113: 895–900.  
195. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M. Fosmidomycin resistance in 
adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol 
Biochem 2003; 67: 2030–3. 
 103 
 
196. Larson TJ, Cantwell JS, van Loo-Bhattacharya AT. Interaction at a distance 
between multiple operators controls the adjacent, divergently transcribed glpTQ-
glpACB operons of Escherichia coli K-12. J Biol Chem 1992; 267: 6114–21. 
197. Olekhnovich IN, Dahl JL, Kadner RJ. Separate contributions of UhpA and CAP to 
activation of transcription of the uhpT promoter of Escherichia coli. J Mol Biol 1999; 
292: 973–86. 
198. Kim DH, Lees WJ, Kempsell KE, Lane WS, Duncan K, Walsh CT. 
Characterization of a Cys115 to Asp Substitution in the Escherichia coli Cell Wall 
Biosynthetic Enzyme UDP-GlcNAc Enolpyruvyl Transferase (MurA) That Confers 
Resistance to Inactivation by the Antibiotic Fosfomycin. Biochemistry (Mosc) 1996; 35: 
4923–8.  
199. Herring CD, Blattner FR. Conditional lethal amber mutations in essential 
Escherichia coli genes. J Bacteriol 2004; 186: 2673–81. 
200. Couce A, Briales A, Rodríguez-Rojas A, Costas C, Pascual Á, Blázquez J. 
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: 
MurA confers clinical resistance at low fitness cost. Antimicrob Agents Chemother 
2012; 56: 2767–9.  
201. Mendoza C, Garcia JM, Llaneza J, Mendez FJ, Hardisson C, Ortiz JM. Plasmid-
determined resistance to fosfomycin in Serratia marcescens. Antimicrob Agents 
Chemother 1980; 18: 215–9. 
202. Arca P, Rico M, Braña AF, Villar CJ, Hardisson C, Suárez JE. Formation of an 
adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance 
in bacteria. Antimicrob Agents Chemother 1988; 32: 1552–6.  
  
104 
203. Zilhao R, Courvalin P. Nucleotide sequence of the fosB gene conferring 
fosfomycin resistance in Staphylococcus epidermidis. FEMS Microbiol Lett 1990; 68: 
267–72.  
204. García P, Arca P, Evaristo Suárez J. Product of fosC, a gene from Pseudomonas 
syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob 
Agents Chemother 1995; 39: 1569–73.  
205. Kitanaka H, Wachino J, Jin W, Yokoyama S, Sasano MA, Hori M, Yamada K, 
Kimura K, Arakawa Y. Novel integron-mediated fosfomycin resistance gene fosK. 
Antimicrob Agents Chemother 2014; 58: 4978–9.  
206. Fillgrove KL, Pakhomova S, Schaab MR, Newcomer ME, Armstrong RN. 
Structure and mechanism of the genomically encoded fosfomycin resistance protein, 
FosX, from Listeria monocytogenes. Biochemistry (Mosc) 2007; 46: 8110–20.  
207. Bernat BA, Laughlin LT, Armstrong RN. Fosfomycin resistance protein (FosA) is 
a manganese metalloglutathione transferase related to glyoxalase I and the extradiol 
dioxygenases. Biochemistry (Mosc) 1997; 36: 3050–5. 
208. Arca P, Hardisson C, Suárez JE. Purification of a glutathione S-transferase that 
mediates fosfomycin resistance in bacteria. Antimicrob Agents Chemother 1990;        
34: 844–8. 
209. Rigsby RE, Brown DW, Dawson E, Lybrand TP, Armstrong RN. A model for 
glutathione binding and activation in the fosfomycin resistance protein, FosA. Arch 
Biochem Biophys 2007; 464: 277–83. 
 105 
 
210. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of 
fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in 
Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. 
Antimicrob Agents Chemother 2010; 54: 3061–4.  
211. Nakamura G, Wachino J, Sato N, Kimura K, Yamada K, Jin W, Shibayama K, 
Yagi T, Kawamura K, Arakawa Y. Practical agar-based disk potentiation test for 
detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing 
glutathione S-transferases. J Clin Microbiol 2014; 52: 3175–9.  
212. Ma Y, Xu X, Guo Q, Wang P, Wang W, Wang M. Characterization of fosA5, a 
new plasmid-mediated fosfomycin resistance gene in Escherichia coli. Lett Appl 
Microbiol 2015; 60: 259–64. 
213. Ho P-L, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, Chow KH. Prevalence and 
molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood 
and urinary Escherichia coli isolates. J Med Microbiol 2013; 62: 1707–13.  
214. Zhao J, Zhu Y, Li Y, Mu XD, You LP, Xu C, Qin P, Ma JL. Coexistence of SFO-1 
and NDM-1 β-lactamase genes and fosfomycin resistance gene fosA3 in an Escherichia 
coli clinical isolate. FEMS Microbiol Lett 2015; 362: 1–7. 
215. Tseng SP, Wang SF, Kuo CY, Huang JW, Hung WC, Ke GM, Lu PL. 
Characterization of fosfomycin resistant extended-spectrum β-lactamase-producing 
Escherichia coli isolates from human and pig in Taiwan. PloS One 2015; 10: e0135864. 
216. Qin S, Fu Y, Zhang Q, Qi H, Weng JG, Xu H, Xu L, Zeng L, Tian H, Rong L, Li 
Y, Shan L, Xu H, Yu Y, Feng X, Liu HM. High incidence and endemic spread of 
  
106 
NDM-1-positive Enterobacteriaceae in Henan province, China. Antimicrob Agents 
Chemother 2014; 58: 4275–82.  
217. Ballestero-Téllez M, Docobo-Pérez F, Portillo-Calderón I, Rodríguez-Martínez 
JM, Racero L, Ramos-Guelfo MS, Blázquez J, Rodríguez-Baño J, Pascual A. Molecular 
insights into fosfomycin resistance in Escherichia coli. J Antimicrob Chemother 2017; 
72: 1303-1309 
218. Burian A, Erdogan Z, Jandrisits C, Zeitlinger M. Impact of pH on activity of 
trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine. 
Pharmacology 2012; 90: 281–7. 
219. Cunha BA. An infectious disease and pharmacokinetic perspective on oral 
antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant 
Gram-negative uropathogens: the importance of urinary antibiotic concentrations and 
urinary pH. Eur J Clin Microbiol Infect Dis 2016; 35: 521–6.  
220. Greenwood D, Jones A, Eley A. Factors influencing the activity of the trometamol 
salt of fosfomycin. Eur J Clin Microbiol 1986; 5: 29–34.  
221. Greenwood D. Fosfomycin trometamol: activity in vitro against urinary tract 
pathogens. Infection 1990; 18 Suppl 2: S60-64. 
222. Shimizu K. Metabolic Regulation of a Bacterial Cell System with Emphasis on 
Escherichia coli Metabolism. Int Sch Res Not 2013; 2013: e645983.  
223. Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy 
SKB, Tognim MCB. Pharmacodynamic evaluation of fosfomycin against E. coli and 
 107 
 
Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin 
activities. Antimicrob Agents Chemother 2017; 25; 61: pii: e02498-16.  
224. Inouye S, Watanabe T, Tsuruoka T, Kitasato I. An increase in the antimicrobial 
activity in vitro of fosfomycin under anaerobic conditions. J Antimicrob Chemother 
1989; 24: 657–66.  
225. Kurabayashi K, Tanimoto K, Tomita H, Hirakawa H. Cooperative actions of CRP-
cAMP and FNR increase the fosfomycin susceptibility of enterohaemorrhagic 
Escherichia coli (EHEC) by elevating the expression of glpT and uhpT under anaerobic 
conditions. Front Microbiol 2017; 8.  
226. Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical 
management of an increasing threat: outpatient urinary tract infections due to multidrug-
resistant uropathogens. Clin Infect Dis 2016; 63: 960–5. 
227. Anon. International Organization for Standardization (ISO). Clinical Laboratory 
Testing and In Vitro Diagnostic Test Systems—Susceptibility Testing of Infectious 
Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices—
Part 1: Reference method for testing the in vitro activity of antimicrobial agents against 
rapidly growing aerobic bacteria involved in infectious diseases . ISO 20776-1. 2006.  
228. Martínez JL, Coque TM, Baquero F. What is a resistance gene? Ranking risk in 
resistomes. Nat Rev Microbiol 2015; 13: 116–23.  
229. Pietsch F. Evolution of antibiotic resistance. Digital comprehensive summaries of 
Uppsala dissertations from the Faculty of Medicine 1150. 67 pp. Uppsala: Acta 
Universitatis 2015.  
  
108 
230. Jorgensen JH, Turnidge JD. Susceptibility test methods: Dilution and disk 
diffusion methods. 2015: 1253–73.  
231. Anon. Methods for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically; Approved Standard—Ninth Edition. 
232. Zeiler HJ. Influence of pH and human urine on the antibacterial activity of 
ciprofloxacin, norfloxacin and ofloxacin. Drugs Exp Clin Res 1985; 11: 335–8. 
233. Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ. Influence of human urine on 
the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli. 
Chemotherapy 1991; 37: 218–23. 
234. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis Off Publ 
Infect Dis Soc Am 2005; 41 Suppl 2: S120-126. 
235. Gocke E. Mechanism of quinolone mutagenicity in bacteria. Mutat Res 1991;    
248: 135–43. 
236. Dörr T, Lewis K, Vulić M. SOS response induces persistence to fluoroquinolones 
in Escherichia coli. PLOS Genet 2009; 5: e1000760.  
237. Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Blázquez J. Antibiotics and 
antibiotic resistance: A bitter fight against evolution. Int J Med Microbiol 2013;       
303: 293–7.  
238. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. 
Antimicrob Agents Chemother 2000; 44: 1771–7. 
 109 
 
239. Justice SS, Hunstad DA, Seed PC, Hultgren SJ. Filamentation by Escherichia coli 
subverts innate defenses during urinary tract infection. Proc Natl Acad Sci U S A 2006; 
103: 19884–9. 
240. McDonald BA, Linde C. Pathogen population genetics, evolutionary potential, and 
durable resistance. Annu Rev Phytopathol 2002; 40: 349–79. 
241. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of 
urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995; 
153: 117–20. 
242. van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld 
GH, Becker MJ, Koster T, Watter-Louis GH, Delfos NM, Ablij HC, Leyten EM, Blrom 
JW, van Dissel JT. Risk factors for fluoroquinolone-resistant Escherichia coli in adults 
with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;   
66: 650–6. 
243. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse 
resistance? Nat Rev Microbiol 2010; 8: 260–71.  
244. Machuca J, Briales A, Labrador G, Díaz-de-Alba P, López-Rojas R, Docobo-Pérez 
F, Martínez-Martínez L, Rodríguez-Baño J, Pachón ME, Pascual A, Rodríguez-
Martínez JM. Interplay between plasmid-mediated and chromosomal-mediated 
fluoroquinolone resistance and bacterial fitness in Escherichia coli. J Antimicrob 
Chemother 2014; 69: 3203–15.  
245. Petersen A, Aarestrup FM, Olsen JE. The in vitro fitness cost of antimicrobial 
resistance in Escherichia coli varies with the growth conditions. FEMS Microbiol Lett 
2009; 299: 53–9.  
  
110 
246. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, Muratani T, 
Matsumoto T, Nakahama C, Tomono K. Molecular mechanisms of fosfomycin 
resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010;          
35: 333–7. 
247. Bi W, Li B, Song J, Hong Y, Zhang X, Liu H, Lu H, Zhou T, Cao J. Antimicrobial 
susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-
lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, 
China. Int J Antimicrob Agents 2017; 50: 29-34 
248. Gordon DM, Riley MA. A theoretical and experimental analysis of bacterial 
growth in the bladder. Mol Microbiol 1992; 6: 555–62. 
249. Li Pira G, Pruzzo C, Schito GC. Monuril and modification of pathogenicity traits 
in resistant microorganisms. Eur Urol 1987; 13 Suppl 1: 92–7. 
250. McDonough KA, Rodriguez A. The myriad roles of cyclic AMP in microbial 
pathogens: from signal to sword. Nat Rev Microbiol 2011; 10: 27–38. 
251. Rodríguez-Rojas A, Maciá MD, Couce A, Gómez C, Castañeda-García A,     
Oliver A, Blázquez J. Assessing the emergence of resistance: the absence of biological 
cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.     
PloS One 2010; 5: e10193. 
252. Thi TD, López E, Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Güelfo JR, 
Castañeda-García A, Blázquez J. Effect of recA inactivation on mutagenesis of 
Escherichia coli exposed to sublethal concentrations of antimicrobials. J Antimicrob 
Chemother 2011; 66: 531–8.  
 111 
 
253. López E, Blázquez J. Effect of subinhibitory concentrations of antibiotics on 
intrachromosomal homologous recombination in Escherichia coli. Antimicrob Agents 
Chemother 2009; 53: 3411–5.  
254. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update.   
Am Fam Physician 2011; 84: 1234–42. 
255. Yü TF. Some unusual features of gouty arthritis in females. Semin Arthritis Rheum 
1977; 6: 247–55. 
256. Guedes-Marques M, Silva C, Ferreira E, Maia P, Carreira A, Campos M. Gitelman 
syndrome with hiponatremia, a rare presentation. Nefrología 2014; 34: 266–8. 
257. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. 
J Am Diet Assoc 1995; 95: 791–7. 
258. Remer T. Influence of diet on acid-base balance. Semin Dial 2000; 13: 221–6. 
259. Losito A, Nunzi EG, Covarelli C, Nunzi E, Ferrara G. Increased acid excretion in 
kidney stone formers with essential hypertension. Nephrol Dial Transplant 2009;       
24: 137–41. 
260. Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine 
composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc 
Nephrol 2006; 17: 1422–8.  
261. Berend K, de Vries APJ, Gans ROB. Physiological approach to assessment of 
acid–base disturbances. N Engl J Med 2014; 371: 1434–45.  
  
112 
262. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association 
of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65: 1422–5.  
263. Ferrando SJ, Levenson JL, Owen JA. Clinical manual of psychopharmacology in 
the medically ill. Washington, DC: American Psychiatric Pub.; 2010.  
264. Kovesdy CP. Metabolic acidosis and kidney disease: does bicarbonate therapy 
slow the progression of CKD? Nephrol Dial Transplant 2012; 27: 3056–62.  
265. Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG. A comparison of the effects 
of potassium citrate and sodium bicarbonate in the alkalinization of urine in 
homozygous cystinuria. Urol Res 2001; 29: 295–302.  
266. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y,     
Nakano S. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and 
antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob Agents 
Chemother 1999; 43: 525–9. 
267. Ortega LM, Arora S. Metabolic acidosis and progression of chronic kidney 
disease: incidence, pathogenesis, and therapeutic options. Nefrol Publicacion Of Soc 
Espanola Nefrol 2012; 32: 724–30. 
268. Dobre M, Rahman M, Hostetter TH. Current status of bicarbonate in CKD. J Am 
Soc Nephrol JASN 2015; 26: 515–23. 
 
 
  
 113 
 
 
 
 
 
Chapter IX 
Annexes 
  
  
114 
  
 115 
 
Annexe I: Additional scientific production 
Congress participation:  
 Las condiciones fisiológicas del tracto urinario afectan la actividad de 
fosfomicina frente a cepas de Escherichia coli con mutaciones en genes 
implicados en su susceptibilidad. Guillermo Martín-Gutiérrez, Fernando 
Docobo, Jerónimo Rodríguez-Beltrán, José Manuel Rodríguez, Javier Aznar, 
Álvaro Pascual y Jesús Blázquez. XXI Congreso Nacional de la SEIMC, 
Málaga (2017).  
 
 Urinary tract physiological conditions as a conductive environment to avoid 
fosfomycin resistance in Escherichia coli. Guillermo Martín-Gutiérrez, 
Fernando Docobo, Jerónimo Rodríguez-Beltrán, José Manuel Rodríguez, Javier 
Aznar, Álvaro Pascual y Jesús Blázquez. X Jornadas Científicas de la Red 
Española de Investigación en Patología Infecciosa, Sevilla (2016). 
 
 La sensibilidad a ciprofloxacino de cepas de Escherichia coli portadoras de 
determinantes plasmídicos de bajo nivel de resistencia a quinolonas disminuye 
en orina a pH ácido y anaerobiosis. Guillermo Martín-Gutiérrez; Jerónimo 
Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; José Antonio Lepe; 
Álvaro Pascual; Javier Aznar; Jesús Blázquez. XIX Congreso Nacional de la 
SEIMC, Sevilla (2015). 
 
 Resistencia a ciprofloxacino encepas de Escherichia coli con mutaciones 
cromosómicas que confieren bajo nivel de resistencia a quinolonas dependiente 
de orina, pH y oxígeno. Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-
Beltrán; José Manuel Rodríguez-Martínez; María del Mar Redero-Cascón; José 
Antonio Lepe; Álvaro Pascual; Javier Aznar; Jesús Blázquez. XIX Congreso 
Nacional de la SEIMC, Sevilla (2015). 
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 Ciprofloxacin susceptible-mediated quinolone resistant Escherichia coli strains 
are ciprofloxacin resistant in urine at acidic pH. Guillermo Martín-Gutiérrez; 
Jerónimo Rodríguez-Beltrán; José Manuel-Rodríguez; Jose Antonio Lepe; Javier 
Aznar; Álvero Pascual; Jesús Blázquez. 25th European Congress of Clinical 
Microbiology and Infectious Diseases in Copenhagen, Denmark (2015). 
 
 pH and anaerobiosis promote ciprofloxacin resistance in low-level 
chromosomally-mediated quinolone resistant Escherichia coli in urine  . 
Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel 
Rodríguez; Jose Antonio Lepe; Javier Aznar; Álvaro Pascual; Jesús Blázquez. 
25th European Congress of Clinical Microbiology and Infectious Diseases in 
Copenhagen, Denmark (2015). 
 
Conferences: 
 Title: Las condiciones del tracto urinario modulan la susceptibilidad de 
Escherichia coli a ciprofloxacino y fosfomicina. 
Scientific event: Seminario Programa de Enfermedades Infecciosas y del 
Sistema Inmunitario. 
Organizer: Instituto de Biomedicina de Sevilla. 
Centre: Instituto de Biomedicina de Sevilla. 
Date: 03/10/2016 
 Title: Actividad antibiótica y respuestas adaptativas de Escherichia coli en 
orina. 
Scientific event: IX Jornada Científicas de la Red Española de Investigación en 
Patología Infecciosa. 
Organizer: Red Española de Investigación en Patología Infecciosa. 
Centre: University Hospital Ramón y Cajal, Madrid.  
Date: 19/11/2014 
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Annexe II  
 
 
Figure 11: Growth curves of ATCC 25113 and nine isogenic strains in MH and urine at pH 7, 6 and 5. EC01: ΔmarR; EC02: gyrA (S83L); EC03: 
ΔmarR-gyrA(S83L); EC04: gyrA(S83L)–parC(S80R); EC05: ΔmarR-gyrA(S83L)-parC(S80R); EC06: gyrA(S83L)-gyrA(D87N); EC07: ΔmarR-
gyrA(S83L)-gyrA(D87N); EC08: gyrA(S83L)-gyrA(D87N)-parC(S80R); EC09: ΔmarR-gyrA(S83L)-gyrA(D87N)-parC(S80R). Error bars represent 
standard errors of the means of re- sults from at least four replicates. MH, Mueller-Hinton; UR, urine; OD, optical density. 
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Annexe III 
Publication I, additional figure. 
 
 Figure 12: Ciprofloxcin susceptibility testing for the strains ATCC 25922, EC02 (gyrA S83L) 
and EC05 (ΔmarR, gyrA S83L, parC S80R) using the gradient MIC strip methodology. MICs 
(µg/mL) are indicated at the right bottom for each condition. MH: Mueller-Hinton agar; UR7: 
urine-agar pH7; UR6: urine-agar pH6; UR5: urine-agar pH5.  
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Annexe IV 
 
Figure 13: Growth curves of E. coli BW25113 and ten isogenic strains with deletions in genes related with FOS-resistance, growing in MH 
and urine at different pH values. Error bars represent standard errors of the means of results from at least ten replicates.  MH, Mueller-Hinton; 
UR, urine; OD, optical density. 
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